Back to announcement
20240503_DGNS_Laporan Informasi dan Fakta Material_31634431_lamp5.pdf
Asset transaction Needs review DGNSSource file signed link, expires in 15 minutes
Extracted text 179
Page 1
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
APAC Genetic Testing Market
Study, Opportunities, and Forecast (2020-2032)
1 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 2
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
About Us
Straits Research is a market intelligence company providing global business information report and services. Our exclusive Blend of quantities
forecasting and trends analysis provides forward-looking insight for thousands of Decision makers. Our experienced team of analysts, Researchers,
and consultants use proprietary data sources and various tools and techniques to gather and analysis information. Our Business reports represent
the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each syndicated research report covers a different sector-such as pharmaceuticals, chemical, energy, food and beverages, contraction, med devices,
consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro Levels. with wider scope and
stratified research methodology, our syndicated reports strive to serve the overall research requirement of clients.
Email Sales@straitsresearch.com I website www.straitsresearch.com
Copyright © 2024 Straits Research
All Rights Reserved. This document contains confidential information and is the exclusive property of Straits Research. Any reproduction,
distribution, or quotation of its contents, in whole or in part, is strictly prohibited without prior written consent from Straits Research. This
document is intended solely for the use of the purchasing client and may not be shared with any third party without explicit authorization. For
further details on usage terms, please refer to the disclaimer page in this report.
2 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 3
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Table of Content
1 EXECUTIVE SUMMARY 18
1.1 Summary 18
1.2 Key Investment Opportunities 20
2 RESEARCH SCOPE & SEGMENTATION 22
2.1 Research Methodology 22
2.2 Market Research Process 22
2.3 Assumptions & Exclusions 25
2.4 Market Scope & Segmentation 26
2.5 Currency & Pricing Considered 28
3 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 4
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3 MARKET TRENDS 29
3.1 Drivers 29
3.1.1 Increasing Prevalence of Genetic Disorders 29
3.1.2 Growing Demand for Personalized Medicine 30
3.1.3 Advancements in Technology Facilitating Genetic Testing 31
3.2 Restraints 32
3.2.1 High Cost Associated with Genetic Testing 32
3.2.2 Limited Accessibility to Genetic Testing in Rural Areas 33
3.3 Opportunity 34
3.3.1 Expansion of genetic testing services into emerging markets. 34
3.4 Challenge 35
3.4.1 Ethical and Privacy Concerns Surrounding Genetic Testing 35
4 MARKET ASSESSMENT 36
4.1 Porters Five Forces Analysis 36
4.1.1 Bargaining Power of Suppliers 37
4.1.2 Bargaining Power of Buyers 38
4 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 5
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.3 Threat of Substitutes 39
4.1.4 Threat of New Entrants 40
4.1.5 Competitive Rivalry 41
4.2 PESTEL Analysis 42
4.2.1 Political 42
4.2.2 Economic 42
4.2.3 Social 42
4.2.4 Technological 43
4.2.5 Environmental 43
4.2.6 Legal 43
4.3 SWOT Analysis 44
4.3.1 Strengths 44
4.3.2 Weaknesses 44
4.3.3 Opportunities 44
4.3.4 Threats 45
5 APAC GENETIC TESTING MARKET 46
5.1 Market Size & Forecast, by Technology 46
5 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 6
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.1 Next Generation Sequencing 47
5.1.2 Array Technology 49
5.1.3 PCR-Based Testing 51
5.1.4 FISH 53
5.1.5 Others 55
5.2 Market Size & Forecast, by Application 56
5.2.1 Ancestry & Ethnicity 57
5.2.2 Traits Screening 59
5.2.3 Genetic Disease Carrier Status 61
5.2.4 New Baby Screening 63
5.2.5 Health And Wellness-Predisposition/Risk/Tendency 65
5.3 Market Size & Forecast, by Product 67
5.3.1 Consumables 68
5.3.2 Equipment 70
5.3.3 Software & Services 72
5.4 Market Size & Forecast, by End User 74
5.4.1 Hospitals & Clinics 75
5.4.2 Diagnostic Laboratories 77
6 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 7
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.4.3 Others 79
6 ASIA-PACIFIC MARKET ANALYSIS 81
6.1 Introduction 81
6.2 Genetic Testing Market by Country 82
6.2.1 Asia-Pacific Genetic Testing Market by Country, USD Million 2020-2032 82
6.3 China 83
6.3.1 Market Size & Forecast, by Technology 83
6.3.2 Market Size & Forecast, by Application 84
6.3.3 Market Size & Forecast, by Product 85
6.3.4 Market Size & Forecast, by End User 86
6.4 South Korea 87
6.4.1 Market Size & Forecast, by Technology 87
6.4.2 Market Size & Forecast, by Application 88
6.4.3 Market Size & Forecast, by Product 89
6.4.4 Market Size & Forecast, by End User 90
6.5 Japan 91
7 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 8
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.5.1 Market Size & Forecast, by Technology 91
6.5.2 Market Size & Forecast, by Application 92
6.5.3 Market Size & Forecast, by Product 93
6.5.4 Market Size & Forecast, by End User 94
6.6 India 95
6.6.1 Market Size & Forecast, by Technology 95
6.6.2 Market Size & Forecast, by Application 96
6.6.3 Market Size & Forecast, by Product 97
6.6.4 Market Size & Forecast, by End User 98
6.7 Australia 99
6.7.1 Market Size & Forecast, by Technology 99
6.7.2 Market Size & Forecast, by Application 100
6.7.3 Market Size & Forecast, by Product 101
6.7.4 Market Size & Forecast, by End User 102
6.8 Indonesia 103
6.8.1 Market Size & Forecast, by Technology 103
6.8.2 Market Size & Forecast, by Application 104
6.8.3 Market Size & Forecast, by Product 105
8 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 9
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.8.4 Market Size & Forecast, by End User 106
6.9 Thailand 107
6.9.1 Market Size & Forecast, by Technology 107
6.9.2 Market Size & Forecast, by Application 108
6.9.3 Market Size & Forecast, by Product 109
6.9.4 Market Size & Forecast, by End User 110
6.10 Rest of Asia Pacific 111
6.10.1 Market Size & Forecast, by Technology 111
6.10.2 Market Size & Forecast, by Application 112
6.10.3 Market Size & Forecast, by Product 113
6.10.4 Market Size & Forecast, by End User 114
7 COMPANY PROFILES 115
7.1 F. Hoffmann-La Roche Ltd 115
7.1.1 Company Overview 116
7.1.2 Key Executives 118
7.1.3 Financial Overview 119
7.1.4 Product Portfolio 119
9 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 10
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.1.5 Key Strategic Developments 120
7.2 Agilent Technologies Inc 121
7.2.1 Company Overview 122
7.2.2 Key Executives 124
7.2.3 Financial Overview 125
7.2.4 Product Portfolio 125
7.3 Abbott Laboratories 127
7.3.1 Company Overview 128
7.3.2 Key Executives 130
7.3.3 Financial Overview 132
7.3.4 Product Portfolio 133
7.3.5 Key Strategic Developments 134
7.4 Illumina Inc 136
7.4.1 Company Overview 137
7.4.2 Key Executives 139
7.4.3 Financial Overview 141
7.4.4 Product Portfolio 141
7.4.5 Key Strategic Developments 143
10 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 11
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.5 Thermos Fisher Scientific Inc 145
7.5.1 Company Overview 146
7.5.2 Key Executives 148
7.5.3 Financial Overview 150
7.5.4 Product Portfolio 150
7.5.5 Key Strategic Developments 153
7.6 CSL Ltd 155
7.6.1 Company Overview 157
7.6.2 Key Executives 158
7.6.3 Financial Overview 159
7.6.4 Product Portfolio 160
7.6.5 Key Strategic Developments 161
7.7 Bio-Rad Laboratories Inc 163
7.7.1 Company Overview 165
7.7.2 Financial Overview 167
7.7.3 Product Portfolio 167
7.7.4 Key Strategic Developments 169
7.8 Myriad Genetics Inc 171
11 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 12
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.8.1 Company Overview 172
7.8.2 Key Executives 175
7.8.3 Financial Overview 176
7.8.4 Product Portfolio 176
7.8.5 Key Strategic Developments 177
12 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 13
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
List of Table
TABLE 1 APAC GENETIC TESTING MARKET INDUSTRY SNAPSHOT, 2023 & 2032 19
TABLE 2 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 46
TABLE 3 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 56
TABLE 4 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 67
TABLE 5 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 74
TABLE 1 ASIA-PACIFIC GENETIC TESTING MARKET BY COUNTRY, USD MILLION 2020-2032 82
TABLE 2 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 83
TABLE 3 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 84
TABLE 4 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 85
TABLE 5 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 86
TABLE 6 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 87
TABLE 7 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 88
TABLE 8 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 89
TABLE 9 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 90
13 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 14
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
TABLE 10 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 91
TABLE 11 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 92
TABLE 12 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 93
TABLE 13 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 94
TABLE 14 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 95
TABLE 15 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 96
TABLE 16 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 97
TABLE 17 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 98
TABLE 18 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 99
TABLE 19 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 100
TABLE 20 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 101
TABLE 21 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 102
TABLE 22 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 103
TABLE 23 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 104
TABLE 24 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 105
TABLE 25 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 106
14 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 15
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
TABLE 26 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 107
TABLE 27 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 108
TABLE 28 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 109
TABLE 29 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 110
TABLE 30 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION) 111
TABLE 31 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION) 112
TABLE 32 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION) 113
TABLE 33 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION) 114
15 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 16
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
List of Figure
FIGURE 1 BARGAINING POWER OF SUPPLIERS 37
FIGURE 2 BARGAINING POWER OF BUYERS 38
FIGURE 3 THREAT OF SUBSTITUTES 39
FIGURE 4 THREAT OF NEW ENTRANTS 40
FIGURE 5 COMPETITIVE RIVALRY 41
FIGURE 6 GENETIC TESTING MARKET, BY NEXT GENERATION SEQUENCING-2020-2032 (USD MILLION) 48
FIGURE 7 GENETIC TESTING MARKET, BY ARRAY TECHNOLOGY-2020-2032 (USD MILLION) 50
FIGURE 8 GENETIC TESTING MARKET, BY PCR-BASED TESTING-2020-2032 (USD MILLION) 52
FIGURE 9 GENETIC TESTING MARKET, BY FISH-2020-2032 (USD MILLION) 54
FIGURE 10 GENETIC TESTING MARKET, BY OTHERS-2020-2032 (USD MILLION) 55
FIGURE 11 GENETIC TESTING MARKET, BY ANCESTRY & ETHNICITY-2020-2032 (USD MILLION) 58
FIGURE 12 GENETIC TESTING MARKET, BY TRAITS SCREENING-2020-2032 (USD MILLION) 60
FIGURE 13 GENETIC TESTING MARKET, BY GENETIC DISEASE CARRIER STATUS-2020-2032 (USD MILLION) 62
FIGURE 14 GENETIC TESTING MARKET, BY NEW BABY SCREENING-2020-2032 (USD MILLION) 64
16 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 17
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
FIGURE 15 GENETIC TESTING MARKET, BY HEALTH AND WELLNESS-PREDISPOSITION/RISK/TENDENCY-2020-2032 (USD
MILLION) 66
FIGURE 16 GENETIC TESTING MARKET, BY CONSUMABLES-2020-2032 (USD MILLION) 69
FIGURE 17 GENETIC TESTING MARKET, BY EQUIPMENT-2020-2032 (USD MILLION) 71
FIGURE 18 GENETIC TESTING MARKET, BY SOFTWARE & SERVICES-2020-2032 (USD MILLION) 73
FIGURE 19 GENETIC TESTING MARKET, BY HOSPITALS & CLINICS-2020-2032 (USD MILLION) 76
FIGURE 20 GENETIC TESTING MARKET, BY DIAGNOSTIC LABORATORIES-2020-2032 (USD MILLION) 78
FIGURE 21 GENETIC TESTING MARKET, BY OTHERS-2020-2032 (USD MILLION) 80
17 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 18
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
1 EXECUTIVE SUMMARY
1.1 Summary
The Asia-Pacific (APAC) region has witnessed significant growth and development in the field of genetic testing in recent years. This
growth can be attributed to several factors, including increasing awareness about personalized medicine, rising prevalence of genetic
disorders, and advancements in healthcare infrastructure and technology across countries in the region.
APAC countries such as China, India, Japan, South Korea, and Australia have emerged as key players in the genetic testing market, driven
by factors such as large patient populations, government initiatives to promote genomic research, and a growing number of private and
public genetic testing laboratories.
Genetic testing services encompass a wide range of applications, including diagnostic testing, predictive and presymptomatic testing,
carrier testing, prenatal and newborn testing, and pharmacogenomics. These tests are used for various purposes, including identifying
genetic predispositions to diseases, guiding treatment decisions, and facilitating targeted therapies.
In addition to the clinical applications, genetic testing is also gaining traction in non-clinical settings such as direct-to-consumer genetic
testing, ancestry testing, and lifestyle-related genetic testing.
Challenges in the APAC genetic testing market include regulatory complexities, ethical considerations, data privacy concerns, and the
need for skilled professionals to interpret and communicate genetic test results effectively.
Despite these challenges, the APAC genetic testing market is poised for continued growth, driven by factors such as increasing
healthcare expenditure, growing demand for personalized medicine, expanding research and development activities, and the
introduction of novel technologies such as next-generation sequencing (NGS) and CRISPR-based gene editing techniques.
18 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 19
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
TABLE 1 APAC GENETIC TESTING MARKET INDUSTRY SNAPSHOT, 2023 & 2032
• 2023: USD 8,794.47 Million
Market Size
• 2032: USD 80,749.79 Million
CAGR • CAGR 26.7%
19 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 20
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
1.2 Key Investment Opportunities
• Expansion of Testing Services: Investing in the expansion of genetic testing services to cover a wider range of genetic disor ders
and conditions prevalent in the APAC region. This could involve setting up new testing facilities, partnering with local healthcare
providers, and developing tests tailored to the genetic diversity of the population.
• Technology Development: Investing in research and development of advanced genetic testing technologies, such as next-
generation sequencing (NGS), microarray analysis, and CRISPR-based gene editing techniques. Developing cost-effective and
high-throughput platforms will enhance the accessibility and affordability of genetic testing services in the APAC region.
• Partnerships and Collaborations: Forming strategic partnerships and collaborations with local healthcare institutions, academic
research centers, and government agencies to leverage their expertise, infrastructure, and networks. Collaborative efforts can
accelerate the adoption of genetic testing and facilitate the development of region-specific testing solutions.
• Direct-to-Consumer (DTC) Testing: Exploring opportunities in the direct-to-consumer genetic testing market by offering
affordable and accessible testing services directly to consumers. This approach can empower individuals to take proactive
control of their health and ancestry information and drive demand for genetic testing services in the APAC region.
• Data Analytics and Interpretation: Investing in bioinformatics and data analytics capabilities to effectively analyze and interpret
genetic data. Developing algorithms and software tools for accurate and actionable interpretation of genetic test results will
enhance the clinical utility of genetic testing and support personalized medicine initiatives in the APAC region.
• Regulatory Compliance and Quality Assurance: Investing in compliance with regulatory requirements and quality assurance
processes to ensure the safety, accuracy, and reliability of genetic testing services. Adhering to international standards and
obtaining regulatory approvals will build trust among healthcare providers and patients in the APAC region.
20 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 21
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
• Education and Training Programs: Investing in education and training programs for healthcare professionals to enhance their
understanding of genetic testing technologies, applications, and ethical considerations. Building a skilled workforce will support
the integration of genetic testing into routine clinical practice and promote evidence-based decision-making in the APAC region.
21 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 22
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
2 RESEARCH SCOPE & SEGMENTATION
2.1 Research Methodology
Our research process is exclusively designed with enough flexibility to ensure best practices for each assignment while retaining the
core elements that ensure accuracy and authenticity. Straits Research has collected key data globally and analyzed it uses a variety of
methods. Market dynamics have been ascertained following a detailed study of the market’s micro and macroeconomic indicators.
2.2 Market Research Process
We, at Straits Research, employ an iterative research methodology supported by a combination of secondary and primary research to
provide the accurate market estimates and forecast. Secondary research was the initial phase of the study, where we conducted data
mining and referred to verified data sources such as independent studies, Security and regulatory published materials, technical
journals, trade magazines, and paid data sources. The data thus gathered was validated through experts' opinions.
22 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 23
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Secondary Primary
Public Domain Sample Size Confirmation
Databases Data Gathering Preparations
Internal Repositories Telephonic Interview
Industry Expert Data Validation
This research played an important role in providing us with an early understanding of the business environment and designing a study
that was in-line with industry dynamics.
Data modeling and forecasting are among our core strengths, where we design unique models to estimate and forecast market growth.
These models are econometric or technical, based on the time period under consideration and are iterative and customizable in nature
so as to minimize errors and improve accuracy.
Attributing to the growing need for granular information, we use a pyramid approach for forecasting, also referred to as the bottom-up
methodology, where we evaluate each regional market separately, taking into consideration domestic as well as international dynamics
to arrive at market numbers. The Europe data is obtained by integrating regional information.
23 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 24
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
A number of tools and statistical modeling techniques are utilized by our team, including software packages such as SPSS and analytical
approaches such as regression, correlation, WMA (Weighted Moving Average), time-series, and variation. All percentage shares, splits,
and breakdowns have been determined using secondary sources and verified through primary sources.
The following parameters were considered while forecasting the market:
• Market drivers, challenges, and opportunities along with their current and expected impacts
• Consumer trends
• Regulatory and political updates and their impact
• Analysis of unmet needs and demand forecasting
Each parameter is assigned with appropriate weightage, and its impact on the market is quantified using the weighted average
technique to derive the expected market growth rate.
All the estimates and forecasts are verified through extensive primary research and experts operating in this market, which include:
• Key market participants
• Manufacturers
• Sales and marketing teams
Finally, we believe that primary research is the most important type that lends us a competitive advantage over our peers. Our
specialized team conducts primary interviews at various stages of the research in order to gain a deep understanding of customer needs,
the business environment, and expected future developments. Interviews for this report were conducted in the form of extensive
24 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 25
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
discussions, which enabled us to obtain penetrating insights into the industry, as well as collect root-level information, in addition to
validating our estimates.
2.3 Assumptions & Exclusions
• The report provides market size with 2022 as the base year in consideration and a yearly forecast till 2031 in terms of Revenue
(USD Million). The estimates for all segments including solutions and certification have been provided on a regional basis for the
forecast period mentioned above.
• We have implemented a mix of top-down and bottom-up approach for market sizing, analyzing the key regional markets,
dynamics, and trends for various solutions and certification. The Europe market has been estimated by integrating the regiona l
markets.
• Market estimates have mainly been based on the feedback obtained through primary interviews with key industry participants
• Inflation has not been accounted for in order to estimate the market
• Totals have been rounded off
25 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 26
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
2.4 Market Scope & Segmentation
The "APAC Market Analysis to 2031" is a specialized and in-depth study of the parent industry with a special focus on the APAC market
trend analysis. The report aims to provide an overview of LEO Satellite Communication Market with detailed market segmentation by
Type, and Therapeutic Areas. The LEO Satellite Communication Market is expected to witness high growth during the forecast period.
The report provides key statistics on the market status of the leading players in LEO Satellite Communication Market and offers key
trends and opportunities in the market.
Segment Sub-Segment
By Technology • Next Generation Sequencing
• Array Technology
• PCR-Based Testing
• FISH
• Others
By Application • Ancestry & Ethnicity
• Traits Screening
• Genetic Disease Carrier Status
• New Baby Screening
• Health And Wellness-Predisposition/Risk/Tendency
26 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 27
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
By Product • Consumables
• Equipment
• Software & Services
By End-user • Hospitals & Clinics
• Diagnostic Laboratories
• Others
By Country • China
• South Korea
• Japan
• India
• Australia
• Indonesia
• Thailand
• Rest of Asia-Pacific
27 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 28
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
2.5 Currency & Pricing Considered
• The report provides an extensive qualitative and quantitative analysis of the current trends and future estimations of the Genetic
Testing Market from 2020 to 2032 to determine the prevailing opportunities.
• A comprehensive analysis of the factors that drive and restrict the growth of the Market is provided.
• Estimations and forecast are based on factors impacting the Market growth, in terms of both value.
• Profiles of leading players operating in the Market are provided to understand the APAC competitive scenario.
• The report provides extensive qualitative insights on the significant segments and regions exhibiting favorable Market growth.
28 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 29
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3 MARKET TRENDS
3.1 Drivers
3.1.1 Increasing Prevalence of Genetic Disorders
The Asia Pacific genetic testing market is experiencing a notable surge driven by the increasing prevalence of genetic disorders across
the region. As medical knowledge and diagnostic capabilities improve, there's a greater awareness and understanding of genetic
conditions among both healthcare professionals and the general population. This heightened awareness leads to more frequent testing,
contributing to the market's growth.
Furthermore, demographic shifts and lifestyle changes in the Asia Pacific region have contributed to the rise in genetic disorders.
Factors such as urbanization, environmental pollution, and changes in dietary habits have been linked to an increased incidence of
genetic conditions. Additionally, factors like consanguineous marriages prevalent in certain cultures can lead to a higher prevalence of
hereditary disorders.
Healthcare infrastructure improvements and greater access to medical services also play a crucial role. As healthcare systems in the
Asia Pacific region become more sophisticated and accessible, individuals have increased opportunities to undergo genetic testing,
further fueling market growth. Moreover, initiatives by governments and healthcare organizations to raise awareness about genetic
disorders and the importance of early diagnosis drive demand for genetic testing services.
29 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 30
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.1.2 Growing Demand for Personalized Medicine
Another key driver propelling the growth of the Asia Pacific genetic testing market is the escalating demand for personalized medicine.
Personalized medicine, also known as precision medicine, tailors medical treatment to the individual characteristics of each patient,
including their genetic makeup. This approach offers numerous benefits, including enhanced treatment efficacy, reduced adverse
effects, and improved patient outcomes.
In recent years, there has been a paradigm shift towards personalized medicine in the Asia Pacific region, driven by advancements in
genomic research and molecular diagnostics. As healthcare providers increasingly recognize the value of personalized approaches, the
demand for genetic testing services has surged. Patients and healthcare professionals alike are seeking genetic insights to guide
treatment decisions, particularly in areas such as oncology, cardiology, and pharmacogenomics.
Moreover, the growing availability and affordability of genetic testing technologies have democratized access to personalized medicine.
As testing becomes more accessible and cost-effective, individuals are more inclined to seek genetic information to inform their
healthcare choices. Additionally, collaborations between research institutions, pharmaceutical companies, and healthcare providers are
driving innovation in personalized medicine, further stimulating market growth.
30 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 31
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.1.3 Advancements in Technology Facilitating Genetic Testing
Advancements in technology are playing a pivotal role in driving the growth of the Asia Pacific genetic testing market. Over the past
decade, significant progress has been made in genomic sequencing technologies, leading to increased accuracy, efficiency, and
affordability of genetic testing.
Next-generation sequencing (NGS) technologies, in particular, have revolutionized genetic testing by enabling the rapid analysis of large
volumes of genetic data. These technologies have greatly expanded the scope of genetic testing applications, allowing for comprehensive
analysis of the entire genome or specific gene panels.
Furthermore, advancements in bioinformatics and data analytics have enhanced the interpretation of genetic test results, providing
deeper insights into disease risk, treatment response, and genetic predispositions. This analytical prowess is invaluable in guiding
clinical decision-making and optimizing patient care.
Moreover, the miniaturization and automation of genetic testing platforms have streamlined laboratory workflows, reducing
turnaround times and increasing testing throughput. These technological innovations have made genetic testing more accessible to
healthcare providers and patients across the Asia Pacific region.
Additionally, ongoing research and development efforts continue to push the boundaries of genetic testing technology, paving the way
for future innovations such as point-of-care genetic testing devices and novel biomarker discovery platforms.
31 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 32
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.2 Restraints
3.2.1 High Cost Associated with Genetic Testing
One of the primary restraints hindering the growth of the Asia Pacific genetic testing market is the high cost associated with genetic
testing procedures. While technological advancements have improved the efficiency and accuracy of genetic testing, they have also
contributed to the overall cost of these tests. The complexity of genetic testing processes, including sample collection, laboratory
analysis, and interpretation of results, requires specialized equipment and expertise, which adds to the overall expense.
The high cost of genetic testing poses a significant barrier, particularly in resource-constrained healthcare settings across the Asia
Pacific region. Patients may be hesitant to undergo genetic testing due to financial constraints, especially when testing is not covered
by public or private insurance schemes. Additionally, healthcare providers may face challenges in justifying the cost of genetic testing
to patients, particularly when there are competing healthcare priorities.
Furthermore, the cost of genetic testing can vary depending on the type and scope of the test required. Comprehensive genomic
sequencing tests, for example, may be prohibitively expensive for many patients, limiting access to advanced diagnostic capabilities.
This disparity in affordability exacerbates healthcare inequalities and restricts access to genetic testing services, particularly for
marginalized communities and underserved populations.
Moreover, the high cost of genetic testing can also deter healthcare providers from offering these services, especially in settings where
reimbursement mechanisms are lacking or inadequate. This reluctance to invest in genetic testing infrastructure further limits
accessibility and widens the gap between those who can afford genetic testing and those who cannot.
32 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 33
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.2.2 Limited Accessibility to Genetic Testing in Rural Areas
Another significant restraint hindering the growth of the Asia Pacific genetic testing market is the limited accessibility to genetic testing
services in rural and remote areas. While major urban centers in the region may have well-equipped healthcare facilities offering genetic
testing, access to these services remains limited in rural and underserved areas.
Several factors contribute to the limited accessibility of genetic testing in rural areas, including inadequate healthcare infrastructure,
shortage of trained personnel, and logistical challenges associated with sample transportation and result delivery. The concentration
of healthcare resources in urban centers often leaves rural populations underserved, with limited access to specialized diagnostic
services such as genetic testing.
Furthermore, cultural and linguistic barriers may also impact the uptake of genetic testing services in rural communities. Lack of
awareness about genetic disorders and testing options, coupled with misconceptions or stigma surrounding genetic conditions, can
deter individuals from seeking testing or adhering to recommended screening protocols.
Additionally, the cost associated with traveling to urban centers for genetic testing can be prohibitive for rural residents, further
exacerbating disparities in access to healthcare services. This geographical barrier not only limits the reach of genetic testing but also
contributes to delayed diagnosis and treatment for individuals residing in rural areas.
33 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 34
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.3 Opportunity
3.3.1 Expansion of genetic testing services into emerging markets.
An exciting opportunity for the Asia Pacific genetic testing market lies in the expansion of genetic testing services into emerging markets
within the region. As economic development accelerates and healthcare infrastructures improve in countries like India, China, and
Southeast Asian nations, there is a growing demand for advanced medical diagnostics, including genetic testing.
Emerging markets present untapped potential for genetic testing companies to expand their reach and capitalize on the increasing
awareness and affordability of healthcare services. These markets offer a large and diverse patient population, providing opportunities
for genetic testing companies to introduce their services and tailor them to local healthcare needs and cultural preferences.
Moreover, advancements in telemedicine and digital health technologies are facilitating the remote delivery of genetic testing services,
overcoming geographical barriers and reaching patients in remote and underserved areas. This expansion into emerging markets not
only contributes to the growth of the genetic testing market but also addresses healthcare disparities by improving access to advanced
diagnostic capabilities.
Furthermore, strategic partnerships and collaborations with local healthcare providers, government agencies, and non-profit
organizations can enhance the adoption of genetic testing services in emerging markets. By leveraging existing healthcare networks
and infrastructure, genetic testing companies can accelerate market penetration and promote widespread adoption of genetic testing
as an essential component of personalized healthcare.
34 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 35
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
3.4 Challenge
3.4.1 Ethical and Privacy Concerns Surrounding Genetic Testing
Despite the tremendous potential for growth, the Asia Pacific genetic testing market faces significant challenges, including ethical and
privacy concerns surrounding genetic testing. As genetic testing technologies become more advanced and accessible, questions
regarding data privacy, informed consent, and potential misuse of genetic information have become increasingly prominent.
Ethical considerations arise from the potential implications of genetic testing results on individuals, families, and society as a whole.
Genetic information is inherently sensitive, and the interpretation of test results can have profound implications for health,
reproduction, and personal identity. Concerns about genetic discrimination, stigmatization, and psychological distress may deter
individuals from undergoing testing or sharing their genetic data.
Furthermore, the global nature of genetic research and testing raises complex ethical issues related to data sharing, informed consent,
and ownership of genetic information. Cross-border data transfers and collaborations between genetic testing companies, research
institutions, and healthcare providers may encounter regulatory and cultural differences regarding data protection and privacy
standards.
Addressing these ethical and privacy concerns requires a multi-faceted approach involving regulatory frameworks, industry standards,
and public education initiatives. Governments and regulatory bodies play a crucial role in establishing clear guidelines and regulations
to protect individuals' genetic privacy rights and ensure ethical practices in genetic testing.
Moreover, genetic testing companies must implement robust security measures, encryption protocols, and data anonymization
techniques to safeguard genetic data against unauthorized access or misuse. Transparent communication and comprehensive informed
consent processes are essential for building trust and empowering individuals to make informed decisions about genetic testing.
35 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 36
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4 MARKET ASSESSMENT
4.1 Porters Five Forces Analysis
36 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 37
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.1 Bargaining Power of Suppliers
Figure 1 Bargaining Power of Suppliers
37 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 38
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.2 Bargaining Power of Buyers
Figure 2 Bargaining Power of Buyers
38 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 39
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.3 Threat of Substitutes
Figure 3 Threat of Substitutes
39 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 40
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.4 Threat of New Entrants
Figure 4 THREAT OF NEW ENTRANTS
40 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 41
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.1.5 Competitive Rivalry
Figure 5 Competitive Rivalry
41 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 42
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.2 PESTEL Analysis
4.2.1 Political
• Regulation and government policies regarding genetic testing vary across countries in the Asia Pacific region.
• Political stability can influence investment and research in genetic testing technologies.
• Trade agreements and international relations may impact the import and export of genetic testing products and services.
4.2.2 Economic
• Economic growth and development influence healthcare spending and accessibility to genetic testing services.
• Income levels and disparities within countries can affect the affordability and adoption of genetic testing.
• Currency fluctuations and economic downturns may impact the purchasing power of consumers and healthcare institutions.
4.2.3 Social
• Cultural attitudes towards genetics and healthcare can influence the acceptance and utilization of genetic testing.
• Demographic trends such as aging populations may drive demand for genetic testing for age-related diseases.
• Public awareness and education about the benefits and risks of genetic testing affect consumer preferences and choices.
42 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 43
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.2.4 Technological
• Advances in genetic testing technologies, such as next-generation sequencing and CRISPR, drive innovation and market growth.
• Integration of genetic testing with other healthcare technologies, such as electronic health records, enhances efficiency and
effectiveness.
• Intellectual property rights and patents play a significant role in shaping the competitive landscape of the genetic testing market.
4.2.5 Environmental
• Environmental factors may influence the prevalence and incidence of genetic disorders within certain populations.
• Sustainable practices and regulations related to genetic testing laboratories and processes are becoming increasingly important.
4.2.6 Legal
• Regulatory frameworks governing genetic testing, data privacy, and patient rights vary across countries and regions.
• Compliance with ethical standards and guidelines, such as those set by professional medical associations, is essential.
• Legal challenges related to liability, informed consent, and genetic discrimination may impact the adoption and growth of genetic
testing services.
43 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 44
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
4.3 SWOT Analysis
4.3.1 Strengths
• Growing awareness and acceptance of genetic testing for disease prevention, diagnosis, and treatment.
• Increasing investment in healthcare infrastructure and research and development activities.
• Presence of leading genetic testing companies and research institutions driving innovation.
• Government support and initiatives to promote personalized medicine and genomics research.
4.3.2 Weaknesses
• Limited access to genetic testing services in rural and underdeveloped areas.
• Affordability barriers for certain segments of the population.
• Lack of standardized regulations and quality control measures across the region.
• Challenges in interpreting and communicating genetic test results accurately.
4.3.3 Opportunities
• Expansion of genetic testing services into emerging markets with unmet healthcare needs.
• Integration of genetic testing into routine healthcare practices and preventive medicine programs.
• Collaborations between academia, industry, and healthcare providers to develop new applications and technologies.
44 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 45
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
• Rising demand for pharmacogenomic testing and precision medicine approaches.
4.3.4 Threats
• Regulatory uncertainties and evolving ethical concerns surrounding genetic testing.
• Competition from alternative diagnostic technologies and non-traditional healthcare providers.
• Data security and privacy risks associated with the storage and sharing of genetic information.
• Potential backlash from communities or advocacy groups regarding genetic testing for sensitive traits or conditions.
45 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 46
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5 APAC GENETIC TESTING MARKET
5.1 Market Size & Forecast, by Technology
TABLE 2 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 1,494.44 2,091.34 2,947.58 4,123.13 5,724.79 7,902.98 10,892.85 14,212.27 18,146.51 22,583.12 27,183.92 32,521.82 38,583.24 28.2%
Array Technology 944.62 1,313.65 1,840.03 2,558.12 3,530.44 4,844.73 6,638.56 8,611.71 10,933.39 13,530.92 16,198.92 19,276.62 22,750.54 27.5%
PCR-Based Testing 434.76 611.61 866.50 1,218.32 1,700.17 2,358.84 3,267.28 4,283.67 5,495.66 6,871.46 8,309.54 9,986.16 11,899.72 28.8%
FISH 192.61 266.94 372.59 516.13 709.66 970.13 1,324.12 1,710.74 2,162.88 2,665.20 3,176.53 3,762.67 4,419.63 26.9%
Others 143.57 197.98 274.90 378.78 518.01 704.28 956.04 1,228.49 1,544.89 1,893.81 2,245.89 2,647.81 3,096.66 26.3%
Total 3,210.00 4,481.52 6,301.61 8,794.47 12,183.07 16,780.96 23,078.86 30,046.88 38,283.33 47,544.52 57,114.81 68,195.08 80,749.79 27.9%
46 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 47
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.1 Next Generation Sequencing
Next Generation Sequencing (NGS) is a pivotal technology driving the Asia Pacific Genetic Testing Market. It offers high throughput,
rapid sequencing, and cost-effectiveness, making it ideal for various genetic testing applications. NGS enables the simultaneous analysis
of multiple genes or entire genomes, allowing researchers and clinicians to uncover intricate genetic variations associated with diseases
and disorders. In the Asia Pacific region, the adoption of NGS is rapidly expanding due to advancements in sequencing platforms ,
reduced sequencing costs, and the growing demand for personalized medicine. NGS facilitates comprehensive genetic analysis, leading
to improved diagnosis, prognosis, and treatment selection for individuals with genetic conditions, thereby fueling the growth of the
genetic testing market
47 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 48
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 6 Genetic Testing Market, by Next Generation Sequencing-2020-2032 (USD Million)
48 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 49
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.2 Array Technology
Array technology is another significant contributor to the Asia Pacific Genetic Testing Market. This technology involves the use of
microarrays to simultaneously analyze thousands of genetic variants within a sample. It enables efficient screening for genetic
abnormalities, such as copy number variations, single nucleotide polymorphisms (SNPs), and gene expression profiles. Array
technology finds extensive applications in research, clinical diagnostics, and pharmacogenomics in the Asia Pacific region. Its ability to
generate large-scale genetic data rapidly and cost-effectively makes it indispensable for studying complex diseases, identifying
biomarkers, and understanding genetic predispositions among diverse populations in the region.
49 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 50
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 7 Genetic Testing Market, by Array Technology-2020-2032 (USD Million)
50 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 51
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.3 PCR-Based Testing
Polymerase Chain Reaction (PCR)-based testing remains a cornerstone in the Asia Pacific Genetic Testing Market. PCR technology
allows the amplification and detection of specific DNA sequences, enabling precise and sensitive genetic testing across various
applications. PCR-based assays are widely utilized for diagnosing genetic disorders, infectious diseases, and cancer biomarkers in the
Asia Pacific region. The versatility, scalability, and automation capabilities of PCR-based testing platforms contribute to their
widespread adoption in both research and clinical settings. With continuous advancements in PCR technology and the developmen t of
novel assays, PCR-based testing continues to drive innovation and growth in the genetic testing market across the Asia Pacific region.
51 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 52
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 8 Genetic Testing Market, by PCR-Based Testing-2020-2032 (USD Million)
52 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 53
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.4 FISH
Fluorescence In Situ Hybridization (FISH) technology plays a vital role in the Asia Pacific Genetic Testing Market, particularly in
cytogenetics and cancer diagnostics. FISH allows for the visualization and mapping of specific DNA sequences within chromosomes,
enabling the detection of chromosomal abnormalities and gene rearrangements with high resolution and sensitivity. In the Asia Pacific
region, FISH is widely used for diagnosing genetic disorders, identifying cancer-specific genetic alterations, and monitoring disease
progression and treatment response. The adoption of FISH technology is driven by its ability to provide valuable insights into genomic
alterations associated with various diseases, thereby facilitating personalized patient management strategies and driving the growth of
the genetic testing market in the Asia Pacific region
53 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 54
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 9 Genetic Testing Market, by FISH-2020-2032 (USD Million)
54 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 55
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.1.5 Others
Figure 10 Genetic Testing Market, by Others-2020-2032 (USD Million)
55 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 56
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2 Market Size & Forecast, by Application
TABLE 3 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 561.70 782.90 1,099.08 1,531.42 2,118.20 2,913.19 4,000.61 5,201.03 6,617.54 8,207.38 9,846.73 11,742.46 13,887.82 27.8%
Traits Screening 171.01 236.83 330.33 457.31 628.48 858.80 1,171.81 1,513.64 1,913.52 2,358.00 2,810.83 3,330.46 3,913.66 26.9%
Genetic Disease Carrier Status 1,242.98 1,728.32 2,420.50 3,364.55 4,642.53 6,369.56 8,726.09 11,317.04 14,364.42 17,772.23 21,270.24 25,303.44 29,853.31 27.5%
New Baby Screening 408.08 573.81 812.56 1,141.93 1,592.78 2,208.73 3,057.81 4,006.95 5,137.91 6,420.65 7,760.06 9,320.47 11,099.96 28.7%
Health And Wellness-
Predisposition/Risk/Tendency 826.22 1,159.65 1,639.14 2,299.26 3,201.07 4,430.68 6,122.54 8,008.22 10,249.94 12,786.25 15,426.94 18,498.25 21,995.05 28.5%
Total 3,210.00 4,481.52 6,301.61 8,794.47 12,183.07 16,780.96 23,078.86 30,046.88 38,283.33 47,544.52 57,114.81 68,195.08 80,749.79 27.9%
56 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 57
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2.1 Ancestry & Ethnicity
Ancestry and ethnicity testing have gained significant traction in the Asia Pacific region due to the growing interest among individuals
in understanding their genetic heritage. This segment is driving the genetic testing market by providing people with insights into their
ancestry, origins, and genetic connections to various populations around the world. In Asia Pacific, where diverse cultures and
ethnicities exist, individuals are particularly keen to explore their ancestral roots. Genetic testing companies offer comprehensive
ancestry reports that analyze DNA to determine geographical origins, ethnic composition, and migration patterns of individuals. This
segment's popularity is further fueled by the increasing availability of direct-to-consumer genetic testing kits, which empower
individuals to explore their genetic ancestry from the comfort of their homes.
57 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 58
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 11 Genetic Testing Market, by Ancestry & Ethnicity-2020-2032 (USD Million)
58 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 59
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2.2 Traits Screening
Traits screening is another driving force in the Asia Pacific genetic testing market, attracting individuals interested in understanding
how their genes influence specific physical and behavioral characteristics. With advancements in genetic technology, individuals can
now uncover insights into various traits such as hair color, eye color, skin type, and even predispositions to certain personality traits.
This segment appeals to a wide audience, including individuals curious about their genetic makeup and those seeking personalized
insights into traits that may impact their daily lives. Moreover, traits screening holds potential applications in fields such as personalized
cosmetics, nutrition, and lifestyle management, further fueling its adoption in the Asia Pacific region.
59 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 60
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 12 Genetic Testing Market, by Traits Screening-2020-2032 (USD Million)
60 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 61
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2.3 Genetic Disease Carrier Status
Genetic testing for carrier status of inherited diseases is driving the Asia Pacific market by offering individuals valuable information
about their risk of passing on genetic disorders to their children. With the prevalence of genetic diseases in certain populations across
Asia Pacific, there is a growing awareness and demand for carrier screening services. Couples planning to start a family are increasingly
turning to genetic testing to assess their risk of transmitting genetic disorders to their offspring. This segment is supported by
advancements in genetic screening technologies, which enable accurate detection of carrier status for a wide range of genetic conditions,
including cystic fibrosis, thalassemia, and sickle cell anemia.
61 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 62
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 13 Genetic Testing Market, by Genetic Disease Carrier Status-2020-2032 (USD Million)
62 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 63
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2.4 New Baby Screening
New baby screening, also known as newborn screening or neonatal screening, plays a crucial role in the early detection and prevention
of genetic disorders in infants. This segment is driving the Asia Pacific genetic testing market by offering parents the opportunity to
screen their newborns for a variety of inherited conditions shortly after birth. Governments and healthcare organizations in the region
are increasingly implementing newborn screening programs to ensure early intervention and treatment for infants with genetic
disorders. The expansion of newborn screening panels to include a broader range of genetic conditions has further boosted the demand
for genetic testing services in this segment.
63 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 64
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 14 Genetic Testing Market, by New Baby Screening-2020-2032 (USD Million)
64 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 65
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.2.5 Health And Wellness-Predisposition/Risk/Tendency
The health and wellness segment focusing on predispositions, risks, and tendencies is driving the Asia Pacific genetic testing market by
empowering individuals to take proactive steps towards managing their health. With a growing emphasis on preventive healthcare in
the region, there is increasing interest in genetic testing for insights into predispositions to various health conditions such as
cardiovascular diseases, cancer, and diabetes. This segment offers personalized health reports based on genetic analysis, enabling
individuals to make informed lifestyle choices, implement preventive measures, and engage in proactive healthcare management. The
availability of comprehensive genetic testing panels that cover a wide range of health-related traits and conditions has fueled the
adoption of genetic testing for health and wellness purposes across Asia Pacific.
65 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 66
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 15 Genetic Testing Market, by Health And Wellness-Predisposition/Risk/Tendency-2020-2032 (USD Million)
66 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 67
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.3 Market Size & Forecast, by Product
TABLE 4 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 1,755.37 2,467.66 3,493.87 4,909.72 6,848.36 9,497.86 13,152.00 17,240.16 22,116.23 27,653.79 33,446.35 40,206.04 47,930.25 28.8%
Equipment 990.34 1,368.99 1,906.03 2,633.91 3,613.12 4,928.20 6,712.04 8,654.10 10,920.19 13,431.91 15,981.66 18,900.93 22,169.25 26.7%
Software & Services 464.29 644.87 901.71 1,250.84 1,721.59 2,354.91 3,214.82 4,152.62 5,246.90 6,458.82 7,686.79 9,088.10 10,650.29 26.9%
Total 3,210.00 4,481.52 6,301.61 8,794.47 12,183.07 16,780.96 23,078.86 30,046.88 38,283.33 47,544.52 57,114.81 68,195.08 80,749.79 27.9%
67 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 68
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.3.1 Consumables
Consumables play a pivotal role in the Asia Pacific genetic testing market by providing the necessary materials for genetic analysis and
testing procedures. These include items such as reagents, DNA extraction kits, and other laboratory supplies essential for sample
preparation, amplification, and analysis. As genetic testing becomes more widespread across the region, the demand for consumables
continues to rise. Factors such as increasing awareness about genetic disorders, advancements in genomics research, and a growing
number of genetic testing laboratories contribute to the growth of this segment. Moreover, the availability of cost-effective consumables
from both domestic and international manufacturers further propels market expansion. Additionally, strategic collaborations between
consumable suppliers and research institutions bolster market penetration and adoption.
68 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 69
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 16 Genetic Testing Market, by Consumables-2020-2032 (USD Million)
69 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 70
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.3.2 Equipment
Equipment forms another critical segment driving the Asia Pacific genetic testing market, encompassing instruments and machinery
required for conducting genetic tests. This includes PCR machines, sequencers, microarrays, and other specialized laboratory
equipment. The continuous evolution of technology has led to the development of advanced equipment with enhanced capabilities, such
as higher throughput and improved sensitivity, thereby facilitating more efficient and accurate genetic testing processes. The growing
emphasis on personalized medicine and the need for precise diagnostics contribute to the increasing demand for sophisticated genetic
testing equipment across the region. Furthermore, investments in research and development activities by key market players to
introduce innovative and user-friendly equipment further stimulate market growth.
70 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 71
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 17 Genetic Testing Market, by Equipment-2020-2032 (USD Million)
71 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 72
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.3.3 Software & Services
Software and services represent a crucial segment driving the Asia Pacific genetic testing market, providing essential tools for data
analysis, interpretation, and reporting. Genetic testing generates vast amounts of data, requiring sophisticated software solutions for
data management, analysis, and visualization. These software platforms enable healthcare professionals and researchers to interpret
genetic test results accurately and derive meaningful insights for clinical decision-making. Additionally, service providers offer a range
of genetic testing services, including counseling, consulting, and interpretation, to support healthcare providers and patients
throughout the testing process. Factors such as the rising adoption of electronic health records, increasing integration of genomics into
clinical practice, and the growing demand for personalized healthcare solutions contribute to the expansion of this segment.
72 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 73
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 18 Genetic Testing Market, by Software & Services-2020-2032 (USD Million)
73 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 74
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.4 Market Size & Forecast, by End User
TABLE 5 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
By End-user 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 1,567.19 2,183.51 3,064.31 4,268.56 5,902.87 8,117.11 11,146.20 14,490.67 18,438.57 22,871.87 27,446.80 32,741.56 38,739.65 27.8%
Diagnostic Laboratories 1,057.70 1,489.64 2,112.89 2,974.19 4,155.33 5,771.88 8,004.18 10,506.54 13,495.27 16,893.97 20,454.31 24,611.35 29,363.48 29.0%
Others 585.11 808.37 1,124.41 1,551.72 2,124.87 2,891.97 3,928.48 5,049.66 6,349.49 7,778.68 9,213.69 10,842.17 12,646.67 26.3%
Total 3,210.00 4,481.52 6,301.61 8,794.47 12,183.07 16,780.96 23,078.86 30,046.88 38,283.33 47,544.52 57,114.81 68,195.08 80,749.79 27.9%
74 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 75
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.4.1 Hospitals & Clinics
Hospitals and clinics serve as primary points of contact for patients seeking medical care, including genetic testing services. The Asia
Pacific region witnesses a surge in the demand for genetic testing in hospitals and clinics due to several factors. Firstly, these healthcare
facilities often have the infrastructure and resources to conduct various types of genetic tests, ranging from prenatal screening to cancer
genetic testing. Moreover, hospitals and clinics have well-established relationships with patients, allowing for seamless integration of
genetic testing into existing healthcare workflows. Additionally, the growing prevalence of genetic disorders and the increasing
awareness about the importance of early detection drive the adoption of genetic testing services in these settings. The availability of
skilled healthcare professionals, including genetic counselors and medical geneticists, further contributes to the growth of genetic
testing in hospitals and clinics across the Asia Pacific region.
75 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 76
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 19 Genetic Testing Market, by Hospitals & Clinics-2020-2032 (USD Million)
76 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 77
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.4.2 Diagnostic Laboratories
Diagnostic laboratories play a pivotal role in the Asia Pacific genetic testing market by offering specialized testing services to patients
and healthcare providers. These laboratories are equipped with advanced technologies and expertise required to perform a wide range
of genetic tests accurately and efficiently. Diagnostic laboratories cater to the needs of various stakeholders, including hospitals, clinics,
research institutions, and pharmaceutical companies. They offer comprehensive genetic testing solutions, including molecular
diagnostics, cytogenetics, and next-generation sequencing, among others. The increasing demand for personalized medicine and the
rising awareness about the role of genetics in disease management drive the growth of diagnostic laboratories specializing in genetic
testing in the Asia Pacific region. Furthermore, advancements in technology, such as automation and high-throughput sequencing
platforms, enhance the capacity and capabilities of diagnostic laboratories, enabling them to meet the growing demand for genetic
testing services effectively.
77 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 78
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 20 Genetic Testing Market, by Diagnostic Laboratories-2020-2032 (USD Million)
78 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 79
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
5.4.3 Others
The "Others" category in the Asia Pacific genetic testing market comprises a diverse range of end-users, including academic and research
institutions, biotechnology companies, and direct-to-consumer genetic testing providers. Academic and research institutions contribute
to the advancement of genetic testing through research and development activities aimed at discovering novel biomarkers, improving
testing methodologies, and expanding the scope of genetic testing applications. Biotechnology companies play a crucial role in
commercializing genetic testing products and services, driving innovation in the field and expanding access to genetic testing across
the region. Direct-to-consumer genetic testing providers offer individuals access to genetic testing services without the need for a
healthcare provider's involvement, fostering greater consumer empowerment and engagement in managing their health. Together,
these diverse end-users contribute to the dynamic growth of the Asia Pacific genetic testing market, driving innovation, accessibility,
and awareness of genetic testing services across the region.
79 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 80
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Figure 21 Genetic Testing Market, by Others-2020-2032 (USD Million)
80 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 81
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6 ASIA-PACIFIC MARKET ANALYSIS
6.1 Introduction
The surge is fueled by several factors such as there's a growing awareness of the benefits of genetic testing for disease prevention, early
detection, and personalized medicine. Secondly, rising disposable incomes and an aging population in the region are creating a larger
market for these tests. Additionally, advancements in technology are making genetic testing more affordable and accessible, further
accelerating its adoption. China and India, with their massive populations and increasing healthcare investments, are expected to be
the key drivers of this market growth in the Asia-Pacific region.
81 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 82
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.2 Genetic Testing Market by Country
6.2.1 Asia-Pacific Genetic Testing Market by Country, USD Million 2020-2032
TABLE 1 ASIA-PACIFIC GENETIC TESTING MARKET BY COUNTRY, USD MILLION 2020-2032
Country 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
China 1,127.10 1,551.94 2,152.26 2,962.41 4,047.49 5,498.43 7,458.13 9,576.53 12,034.05 14,739.94 17,463.75 20,565.30 24,016.89 26.2%
South Korea 339.97 471.33 658.15 912.11 1,254.77 1,716.29 2,343.99 3,030.45 3,834.29 4,728.72 5,641.03 6,688.53 7,864.77 27.0%
Japan 607.08 824.42 1,127.62 1,530.75 2,062.71 2,763.65 3,697.15 4,682.07 5,802.75 7,009.88 8,191.14 9,513.38 10,957.44 24.4%
India 421.26 622.83 927.45 1,370.72 2,010.93 2,933.29 4,272.20 5,890.27 7,947.76 10,452.85 13,297.87 16,814.55 21,084.96 35.5%
Australia 202.55 280.19 390.36 539.78 740.90 1,011.14 1,377.84 1,777.37 2,243.78 2,760.98 3,286.28 3,887.78 4,561.23 26.8%
Indonesia 67.80 98.53 144.23 209.54 307.98 450.09 667.29 936.52 1,287.51 1,731.69 2,259.16 2,937.52 3,798.32 38.0%
Thailand 60.71 85.02 119.92 167.87 233.28 322.31 444.65 580.69 742.17 924.56 1,114.11 1,334.37 1,584.93 28.3%
Rest of Asia-Pacific 383.55 547.27 781.63 1,101.28 1,525.03 2,085.76 2,817.62 3,572.97 4,391.02 5,195.90 5,861.46 6,453.65 6,881.25 22.6%
Total 3,210.00 4,481.52 6,301.61 8,794.47 12,183.07 16,780.96 23,078.86 30,046.88 38,283.33 47,544.52 57,114.81 68,195.08 80,749.79 27.9%
82 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 83
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.3 China
China represents a significant growth opportunity in the Asia Pacific genetic testing market due to its large population, increasing
healthcare expenditure, and expanding healthcare infrastructure. Rapid advancements in biotechnology and genetics research
contribute to the growing demand for genetic testing services in China. Government initiatives to promote precision medicine and
genetic research, along with rising awareness among the population regarding genetic diseases, drive market growth in the region.
6.3.1 Market Size & Forecast, by Technology
TABLE 2 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation Sequencing 528.74 729.93 1,014.90 1,400.55 1,918.51 2,613.00 3,553.48 4,574.63 5,763.45 7,077.67 8,407.27 9,926.04 11,622.01 26.5%
Array Technology 328.20 450.02 621.48 851.83 1,158.96 1,567.83 2,117.71 2,707.82 3,388.44 4,132.96 4,876.17 5,718.11 6,649.83 25.6%
PCR-Based Testing 155.25 215.52 301.34 418.18 576.04 788.96 1,078.93 1,396.76 1,769.61 2,185.30 2,610.37 3,099.21 3,649.07 27.2%
FISH 70.92 97.05 133.75 182.97 248.44 335.42 452.16 577.01 720.61 877.19 1,032.88 1,208.81 1,402.98 25.4%
Others 43.99 59.42 80.78 108.89 145.54 193.22 255.85 320.31 391.94 466.83 537.06 613.13 693.00 22.8%
Total 1,127.10 1,551.94 2,152.26 2,962.41 4,047.49 5,498.43 7,458.13 9,576.53 12,034.05 14,739.94 17,463.75 20,565.30 24,016.89 26.2%
83 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 84
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.3.2 Market Size & Forecast, by Application
TABLE 3 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 196.98 270.66 374.58 514.51 701.51 951.01 1,287.28 1,649.49 2,068.47 2,528.32 2,989.31 3,512.90 4,093.97 25.9%
Traits Screening 58.48 79.90 109.94 150.13 203.52 274.31 369.16 470.29 586.35 712.56 837.62 978.65 1,133.94 25.2%
Genetic Disease Carrier Status 434.38 595.61 822.54 1,127.42 1,533.92 2,075.07 2,802.85 3,583.88 4,484.70 5,470.09 6,453.75 7,568.09 8,801.24 25.6%
New Baby Screening 145.01 201.28 281.39 390.45 537.77 736.45 1,007.00 1,303.48 1,651.22 2,038.84 2,435.12 2,890.77 3,403.22 27.2%
Health And Wellness-
Predisposition/Risk/Tendency 292.24 404.48 563.80 779.90 1,070.77 1,461.60 1,991.84 2,569.38 3,243.31 3,990.14 4,747.95 5,614.90 6,584.52 26.7%
Total 1,127.10 1,551.94 2,152.26 2,962.41 4,047.49 5,498.43 7,458.13 9,576.53 12,034.05 14,739.94 17,463.75 20,565.30 24,016.89 26.2%
84 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 85
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.3.3 Market Size & Forecast, by Product
TABLE 4 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 604.04 837.30 1,168.97 1,619.79 2,227.93 3,046.91 4,160.58 5,378.18 6,803.66 8,389.39 10,006.34 11,862.51 13,946.39 27.0%
Equipment 354.93 483.96 664.62 905.89 1,225.64 1,648.79 2,214.64 2,815.98 3,504.14 4,250.24 4,986.58 5,814.98 6,724.77 24.9%
Software & Services 168.13 230.68 318.66 436.73 593.91 802.74 1,082.91 1,382.37 1,726.25 2,100.32 2,470.83 2,887.82 3,345.73 25.4%
Total 1,127.10 1,551.94 2,152.26 2,962.41 4,047.49 5,498.43 7,458.13 9,576.53 12,034.05 14,739.94 17,463.75 20,565.30 24,016.89 26.2%
85 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 86
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.3.4 Market Size & Forecast, by End User
TABLE 5 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 532.43 730.78 1,010.21 1,386.03 1,887.65 2,556.14 3,456.08 4,423.56 5,540.95 6,765.15 7,989.65 9,378.53 10,917.55 25.8%
Diagnostic
Laboratories 373.40 518.98 726.50 1,009.38 1,392.07 1,908.89 2,613.60 3,387.53 4,296.89 5,312.58 6,353.51 7,552.28 8,902.79 27.4%
Others 221.27 302.18 415.54 567.00 767.77 1,033.40 1,388.44 1,765.44 2,196.21 2,662.22 3,120.59 3,634.50 4,196.54 24.9%
Total 1,127.10 1,551.94 2,152.26 2,962.41 4,047.49 5,498.43 7,458.13 9,576.53 12,034.05 14,739.94 17,463.75 20,565.30 24,016.89 26.2%
86 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 87
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.4 South Korea
South Korea's genetic testing market benefits from its advanced healthcare infrastructure, strong research and development
capabilities, and government support for precision medicine initiatives. The country's aging population and increasing incidence of
chronic diseases drive the demand for genetic testing services for early disease detection and personalized treatment strategies.
Collaboration between academia, industry, and government entities fosters innovation and market expansion in South Korea.
6.4.1 Market Size & Forecast, by Technology
TABLE 6 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation Sequencing 153.43 213.26 298.56 414.84 572.16 784.63 1,074.37 1,392.61 1,766.57 2,184.30 2,612.46 3,105.60 3,661.21 27.4%
Array Technology 105.09 145.08 201.74 278.41 381.40 519.50 706.52 909.61 1,146.06 1,407.48 1,671.99 1,974.16 2,311.61 26.5%
PCR-Based Testing 42.48 59.38 83.59 116.80 162.00 223.40 307.61 400.97 511.49 635.98 764.91 914.39 1,084.02 28.1%
FISH 19.82 27.31 37.90 52.21 71.38 97.03 131.70 169.21 212.78 260.79 309.19 364.34 425.77 26.3%
Others 19.15 26.30 36.35 49.85 67.83 91.73 123.79 158.05 197.40 240.16 282.48 330.03 382.16 25.4%
Total 339.97 471.33 658.15 912.11 1,254.77 1,716.29 2,343.99 3,030.45 3,834.29 4,728.72 5,641.03 6,688.53 7,864.77 27.0%
87 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 88
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.4.2 Market Size & Forecast, by Application
TABLE 7 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 55.73 77.10 107.43 148.58 203.97 278.41 379.44 489.55 618.12 760.72 905.61 1,071.54 1,257.37 26.8%
Traits Screening 23.53 32.37 44.84 61.65 84.15 114.20 154.75 198.50 249.18 304.90 360.87 424.53 495.27 26.0%
Genetic Disease Carrier Status 136.70 188.73 262.43 362.17 496.14 675.78 919.07 1,183.25 1,490.83 1,830.90 2,174.98 2,568.05 3,007.02 26.5%
New Baby Screening 44.85 62.68 88.22 123.26 170.93 235.69 324.49 422.91 539.42 670.62 806.47 963.95 1,142.63 28.1%
Health And Wellness-
Predisposition/Risk/Tendency 79.17 110.47 155.23 216.46 299.58 412.20 566.24 736.24 936.74 1,161.57 1,393.10 1,660.45 1,962.48 27.8%
Total 339.97 471.33 658.15 912.11 1,254.77 1,716.29 2,343.99 3,030.45 3,834.29 4,728.72 5,641.03 6,688.53 7,864.77 27.0%
88 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 89
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.4.3 Market Size & Forecast, by Product
TABLE 8 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 191.71 267.57 376.13 524.77 726.75 1,000.73 1,375.90 1,790.78 2,280.99 2,831.95 3,400.98 4,059.56 4,805.50 27.9%
Equipment 102.03 140.08 193.69 265.82 362.12 490.48 663.34 849.25 1,064.05 1,299.48 1,535.08 1,802.40 2,098.72 25.8%
Software & Services 46.23 63.68 88.32 121.52 165.90 225.07 304.75 390.42 489.25 597.29 704.97 826.56 960.55 25.8%
Total 339.97 471.33 658.15 912.11 1,254.77 1,716.29 2,343.99 3,030.45 3,834.29 4,728.72 5,641.03 6,688.53 7,864.77 27.0%
89 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 90
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.4.4 Market Size & Forecast, by End User
TABLE 9 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 166.36 229.90 320.00 442.06 606.18 826.49 1,125.15 1,450.02 1,828.77 2,248.16 2,673.32 3,159.60 3,703.37 26.6%
Diagnostic Laboratories 113.18 158.39 223.25 312.30 433.67 598.76 825.44 1,077.22 1,375.77 1,712.66 2,062.31 2,468.27 2,929.65 28.2%
Others 60.43 83.04 114.91 157.75 214.92 291.04 393.40 503.22 629.74 767.89 905.40 1,060.65 1,231.76 25.7%
Total 339.97 471.33 658.15 912.11 1,254.77 1,716.29 2,343.99 3,030.45 3,834.29 4,728.72 5,641.03 6,688.53 7,864.77 27.0%
90 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 91
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.5 Japan
Japan is a major driver of the Asia Pacific genetic testing market due to its advanced healthcare infrastructure, high healthcare
expenditure, and growing geriatric population. The country's emphasis on precision medicine and personalized healthcare drives the
demand for genetic testing. Additionally, the presence of key market players and government initiatives promoting genetic research
further fuel market growth. Japan's regulatory framework supports the adoption of genetic testing, ensuring high-quality standards
and patient safety.
6.5.1 Market Size & Forecast, by Technology
TABLE 10 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 286.27 389.76 534.49 727.45 982.79 1,320.17 1,770.67 2,248.18 2,793.52 3,383.39 3,963.77 4,615.54 5,329.91 24.8%
Array Technology 175.30 237.06 322.88 436.48 585.70 781.44 1,041.01 1,312.81 1,620.22 1,949.07 2,267.98 2,623.04 3,008.54 23.9%
PCR-Based Testing 85.00 116.38 160.48 219.64 298.40 403.09 543.67 694.15 867.36 1,056.39 1,244.54 1,457.31 1,692.29 25.5%
FISH 37.73 50.92 69.21 93.38 125.05 166.52 221.39 278.64 343.20 412.03 478.50 552.31 632.22 23.7%
Others 22.79 30.30 40.55 53.79 70.76 92.44 120.41 148.29 178.45 208.99 236.35 265.18 294.48 20.8%
Total 607.08 824.42 1,127.62 1,530.75 2,062.71 2,763.65 3,697.15 4,682.07 5,802.75 7,009.88 8,191.14 9,513.38 10,957.44 24.4%
91 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 92
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.5.2 Market Size & Forecast, by Application
TABLE 11 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 105.66 143.19 195.44 264.76 356.03 476.02 635.48 803.11 993.27 1,197.40 1,396.28 1,618.30 1,860.08 24.2%
Traits Screening 31.01 41.78 56.70 76.37 102.10 135.72 180.14 226.34 278.32 333.58 386.74 445.65 509.27 23.5%
Genetic Disease Carrier Status 232.01 313.75 427.34 577.69 775.19 1,034.26 1,377.81 1,737.55 2,144.41 2,579.65 3,001.73 3,471.67 3,981.89 23.9%
New Baby Screening 79.37 108.66 149.82 205.03 278.51 376.17 507.29 647.63 809.13 985.35 1,160.69 1,358.95 1,577.87 25.5%
Health And Wellness-
Predisposition/Risk/Tendency 159.03 217.04 298.31 406.91 550.89 741.49 996.42 1,267.45 1,577.62 1,913.89 2,245.70 2,618.81 3,028.33 25.0%
Total 607.08 824.42 1,127.62 1,530.75 2,062.71 2,763.65 3,697.15 4,682.07 5,802.75 7,009.88 8,191.14 9,513.38 10,957.44 24.4%
92 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 93
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.5.3 Market Size & Forecast, by Product
TABLE 12 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 329.73 450.78 620.69 848.25 1,150.70 1,552.07 2,090.25 2,664.85 3,324.85 4,043.45 4,756.52 5,561.39 6,448.53 25.3%
Equipment 187.47 252.10 341.46 459.02 612.51 812.65 1,076.55 1,350.07 1,656.91 1,982.09 2,293.53 2,637.81 3,008.61 23.2%
Software & Services 89.88 121.54 165.46 223.48 299.50 398.93 530.35 667.16 820.99 984.34 1,141.09 1,314.18 1,500.30 23.6%
Total 607.08 824.42 1,127.62 1,530.75 2,062.71 2,763.65 3,697.15 4,682.07 5,802.75 7,009.88 8,191.14 9,513.38 10,957.44 24.4%
93 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 94
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.5.4 Market Size & Forecast, by End User
TABLE 13 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 284.95 385.72 525.89 711.62 955.86 1,276.58 1,702.31 2,148.92 2,654.75 3,196.76 3,723.52 4,310.74 4,949.21 24.0%
Diagnostic Laboratories 204.92 280.90 387.83 531.43 722.85 977.60 1,320.11 1,687.51 2,111.11 2,574.27 3,036.37 3,559.68 4,138.59 25.6%
Others 117.21 157.79 213.90 287.70 384.00 509.48 674.73 845.64 1,036.89 1,238.85 1,431.26 1,642.95 1,869.64 23.1%
Total 607.08 824.42 1,127.62 1,530.75 2,062.71 2,763.65 3,697.15 4,682.07 5,802.75 7,009.88 8,191.14 9,513.38 10,957.44 24.4%
94 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 95
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.6 India
India's genetic testing market is driven by factors such as the rising prevalence of genetic disorders, increasing healthcare awareness,
and growing disposable income. The country's large population, coupled with rising healthcare expenditure and government initiatives
to promote healthcare infrastructure development, creates a favorable environment for market growth. Additionally, advancements in
technology and the availability of affordable genetic testing solutions contribute to the expansion of the market in India.
6.6.1 Market Size & Forecast, by Technology
TABLE 14 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 190.38 282.20 421.31 624.29 918.23 1,342.87 1,960.90 2,710.58 3,666.87 4,835.13 6,167.07 7,818.18 9,829.17 35.8%
Array Technology 128.83 189.67 281.26 413.94 604.72 878.40 1,273.99 1,749.15 2,350.24 3,078.06 3,899.43 4,909.99 6,131.19 34.9%
PCR-Based
Testing 52.57 78.37 117.65 175.31 259.31 381.35 559.97 778.40 1,058.91 1,404.11 1,800.94 2,295.89 2,902.61 36.6%
FISH 22.37 32.87 48.64 71.45 104.17 151.01 218.58 299.51 401.64 524.98 663.74 834.09 1,039.47 34.6%
Others 27.11 39.72 58.59 85.74 124.49 179.66 258.75 352.64 470.10 610.57 766.69 956.39 1,182.52 33.9%
Total 421.26 622.83 927.45 1,370.72 2,010.93 2,933.29 4,272.20 5,890.27 7,947.76 10,452.85 13,297.87 16,814.55 21,084.96 35.5%
95 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 96
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.6.2 Market Size & Forecast, by Application
TABLE 15 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 77.55 114.42 170.04 250.78 367.15 534.44 776.76 1,068.74 1,439.06 1,888.71 2,397.78 3,025.59 3,786.12 35.2%
Traits Screening 21.95 32.20 47.58 69.76 101.54 146.96 212.36 290.49 388.89 507.46 640.51 803.55 999.73 34.4%
Genetic Disease Carrier Status 166.74 245.49 364.03 535.75 782.69 1,136.90 1,648.91 2,263.90 3,041.88 3,983.90 5,046.98 6,354.94 7,935.51 34.9%
New Baby Screening 47.35 70.57 105.94 157.83 233.42 343.24 503.95 700.44 952.74 1,263.16 1,619.95 2,064.90 2,610.25 36.6%
Health And Wellness-
Predisposition/Risk/Tendency 107.67 160.14 239.88 356.59 526.13 771.76 1,130.22 1,566.71 2,125.20 2,809.63 3,592.64 4,565.57 5,753.34 36.2%
Total 421.26 622.83 927.45 1,370.72 2,010.93 2,933.29 4,272.20 5,890.27 7,947.76 10,452.85 13,297.87 16,814.55 21,084.96 35.5%
96 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 97
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.6.3 Market Size & Forecast, by Product
TABLE 16 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 233.31 347.25 520.57 774.53 1,143.90 1,679.77 2,462.91 3,418.51 4,643.55 6,148.13 7,873.97 10,023.07 12,652.95 36.4%
Equipment 130.22 190.65 281.13 411.44 597.72 863.39 1,245.24 1,700.14 2,271.65 2,958.55 3,727.12 4,666.86 5,795.09 34.2%
Software & Services 57.74 84.93 125.76 184.76 269.31 390.13 564.05 771.63 1,032.57 1,346.17 1,696.77 2,124.62 2,636.92 34.4%
Total 421.26 622.83 927.45 1,370.72 2,010.93 2,933.29 4,272.20 5,890.27 7,947.76 10,452.85 13,297.87 16,814.55 21,084.96 35.5%
97 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 98
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.6.4 Market Size & Forecast, by End User
TABLE 17 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 233.34 343.89 510.45 752.00 1,099.69 1,598.97 2,321.37 3,190.35 4,290.98 5,625.42 7,133.64 8,991.32 11,238.80 35.1%
Diagnostic Laboratories 127.18 189.81 285.30 425.63 630.29 928.04 1,364.36 1,898.81 2,586.17 3,433.31 4,408.87 5,627.26 7,122.81 36.8%
Others 60.74 89.13 131.71 193.10 280.94 406.29 586.47 801.12 1,070.62 1,394.12 1,755.36 2,195.97 2,723.35 34.2%
Total 421.26 622.83 927.45 1,370.72 2,010.93 2,933.29 4,272.20 5,890.27 7,947.76 10,452.85 13,297.87 16,814.55 21,084.96 35.5%
98 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 99
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.7 Australia
Australia's well-established healthcare system, advanced genetic research capabilities, and increasing adoption of precision medicine
drive the genetic testing market in the country. Growing awareness among healthcare professionals and patients regarding the benefits
of genetic testing for disease diagnosis, treatment selection, and personalized healthcare drives market growth. Moreover,
collaborations between academic institutions, research organizations, and industry players further stimulate innovation and market
expansion.
6.7.1 Market Size & Forecast, by Technology
TABLE 18 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 91.77 127.28 177.79 246.48 339.19 464.10 634.05 820.03 1,037.90 1,280.44 1,528.01 1,812.36 2,131.82 27.1%
Array Technology 61.68 84.97 117.88 162.32 221.87 301.53 409.16 525.59 660.73 809.62 959.62 1,130.51 1,320.78 26.2%
PCR-Based Testing 25.49 35.54 49.93 69.60 96.32 132.53 182.08 236.81 301.40 373.92 448.72 535.20 633.07 27.8%
FISH 10.69 14.69 20.35 27.96 38.14 51.73 70.06 89.82 112.69 137.81 163.02 191.66 223.48 26.0%
Others 12.92 17.70 24.42 33.42 45.38 61.24 82.49 105.13 131.06 159.18 186.92 218.04 252.09 25.2%
Total 202.55 280.19 390.36 539.78 740.90 1,011.14 1,377.84 1,777.37 2,243.78 2,760.98 3,286.28 3,887.78 4,561.23 26.8%
99 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 100
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.7.2 Market Size & Forecast, by Application
TABLE 19 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 37.21 51.37 71.42 98.55 134.99 183.84 250.00 321.82 405.42 497.84 591.33 698.11 817.34 26.5%
Traits Screening 10.47 14.37 19.87 27.26 37.12 50.26 67.95 86.97 108.93 132.99 157.05 184.34 214.57 25.8%
Genetic Disease Carrier Status 79.84 109.97 152.57 210.09 287.16 390.26 529.57 680.26 855.17 1,047.88 1,242.03 1,463.20 1,709.47 26.2%
New Baby Screening 22.95 32.00 44.95 62.66 86.70 119.27 163.84 213.06 271.15 336.34 403.57 481.29 569.23 27.8%
Health And Wellness-
Predisposition/Risk/Tendency 52.08 72.47 101.55 141.23 194.93 267.50 366.48 475.26 603.11 745.93 892.31 1,060.84 1,250.63 27.4%
Total 202.55 280.19 390.36 539.78 740.90 1,011.14 1,377.84 1,777.37 2,243.78 2,760.98 3,286.28 3,887.78 4,561.23 26.8%
100 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 101
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.7.3 Market Size & Forecast, by Product
TABLE 20 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 112.93 157.26 220.57 307.05 424.28 582.92 799.65 1,038.44 1,319.74 1,634.84 1,958.93 2,333.03 2,755.53 27.6%
Equipment 62.00 84.93 117.17 160.44 218.08 294.72 397.69 508.01 635.07 773.85 912.10 1,068.54 1,241.42 25.5%
Software & Services 27.62 37.99 52.62 72.29 98.54 133.50 180.50 230.91 288.97 352.29 415.24 486.21 564.29 25.6%
Total 202.55 280.19 390.36 539.78 740.90 1,011.14 1,377.84 1,777.37 2,243.78 2,760.98 3,286.28 3,887.78 4,561.23 26.8%
101 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 102
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.7.4 Market Size & Forecast, by End User
TABLE 21 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 111.84 154.21 214.16 295.18 403.87 549.42 746.28 959.60 1,207.54 1,481.13 1,757.29 2,072.28 2,423.47 26.4%
Diagnostic
Laboratories 61.73 86.19 121.21 169.18 234.41 322.91 444.17 578.35 736.98 915.40 1,099.81 1,313.35 1,555.35 28.0%
Others 28.99 39.79 54.99 75.41 102.62 138.80 187.40 239.42 299.26 364.46 429.19 502.15 582.41 25.5%
Total 202.55 280.19 390.36 539.78 740.90 1,011.14 1,377.84 1,777.37 2,243.78 2,760.98 3,286.28 3,887.78 4,561.23 26.8%
102 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 103
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.8 Indonesia
Indonesia's genetic testing market is driven by factors such as increasing healthcare expenditure, rising awareness about genetic
diseases, and government initiatives to improve healthcare infrastructure. The country's large population, coupled with a growing
middle class and increasing access to healthcare services, creates opportunities for market growth. Moreover, partnerships between
local and international companies enhance the availability of genetic testing solutions, further stimulating market expansion.
6.8.1 Market Size & Forecast, by Technology
TABLE 22 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 31.80 46.34 68.01 99.06 145.98 213.89 317.93 447.37 616.62 831.50 1,087.59 1,417.82 1,838.05 38.3%
Array Technology 19.74 28.57 41.65 60.25 88.19 128.34 189.47 264.81 362.53 485.55 630.80 816.77 1,051.69 37.4%
PCR-Based Testing 9.34 13.68 20.19 29.58 43.83 64.58 96.53 136.59 189.33 256.73 337.69 442.69 577.11 39.1%
FISH 4.27 6.16 8.96 12.94 18.90 27.46 40.46 56.43 77.10 103.05 133.62 172.66 221.88 37.1%
Others 2.65 3.77 5.41 7.70 11.07 15.82 22.89 31.32 41.93 54.84 69.48 87.58 109.60 34.3%
Total 67.80 98.53 144.23 209.54 307.98 450.09 667.29 936.52 1,287.51 1,731.69 2,259.16 2,937.52 3,798.32 38.0%
103 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 104
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.8.2 Market Size & Forecast, by Application
TABLE 23 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 11.85 17.18 25.10 36.39 53.38 77.85 115.17 161.31 221.30 297.03 386.71 501.78 647.47 37.7%
Traits Screening 3.52 5.07 7.37 10.62 15.49 22.45 33.03 45.99 62.73 83.71 108.36 139.79 179.34 36.9%
Genetic Disease Carrier Status 26.13 37.81 55.12 79.74 116.72 169.86 250.77 350.48 479.81 642.64 834.88 1,081.01 1,391.94 37.4%
New Baby Screening 8.72 12.78 18.86 27.62 40.92 60.28 90.10 127.47 176.66 239.53 315.01 412.91 538.23 39.1%
Health And Wellness-
Predisposition/Risk/Tendency 17.58 25.68 37.78 55.16 81.48 119.64 178.21 251.27 347.00 468.77 614.21 802.02 1,041.36 38.6%
Total 67.80 98.53 144.23 209.54 307.98 450.09 667.29 936.52 1,287.51 1,731.69 2,259.16 2,937.52 3,798.32 38.0%
104 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 105
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.8.3 Market Size & Forecast, by Product
TABLE 24 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 36.33 53.16 78.34 114.57 169.53 249.41 372.25 525.95 727.91 985.61 1,294.45 1,694.42 2,205.65 38.9%
Equipment 21.35 30.73 44.54 64.07 93.26 134.97 198.15 275.38 374.90 499.33 645.08 830.60 1,063.54 36.6%
Software & Services 10.11 14.65 21.35 30.89 45.19 65.71 96.89 135.19 184.69 246.75 319.63 412.49 529.13 37.1%
Total 67.80 98.53 144.23 209.54 307.98 450.09 667.29 936.52 1,287.51 1,731.69 2,259.16 2,937.52 3,798.32 38.0%
105 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 106
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.8.4 Market Size & Forecast, by End User
TABLE 25 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 32.03 46.40 67.70 98.04 143.63 209.24 309.22 432.59 592.82 794.79 1,033.57 1,339.62 1,726.63 37.5%
Diagnostic Laboratories 22.46 32.95 48.68 71.39 105.92 156.26 233.84 331.28 459.72 624.13 821.91 1,078.76 1,408.00 39.3%
Others 13.31 19.19 27.85 40.10 58.42 84.59 124.23 172.65 234.97 312.76 403.69 519.15 663.69 36.6%
Total 67.80 98.53 144.23 209.54 307.98 450.09 667.29 936.52 1,287.51 1,731.69 2,259.16 2,937.52 3,798.32 38.0%
106 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 107
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.9 Thailand
6.9.1 Market Size & Forecast, by Technology
TABLE 26 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 29.30 41.14 58.18 81.66 113.76 157.59 217.97 285.40 365.70 456.76 551.83 662.64 789.10 28.7%
Array Technology 16.88 23.54 33.06 46.09 63.78 87.76 120.56 156.78 199.54 247.54 297.04 354.27 419.03 27.8%
PCR-Based Testing 9.15 12.92 18.37 25.93 36.32 50.60 70.38 92.66 119.40 149.97 182.20 220.01 263.47 29.4%
FISH 3.57 4.97 6.96 9.69 13.38 18.37 25.18 32.69 41.52 51.40 61.56 73.27 86.49 27.5%
Others 1.81 2.45 3.34 4.51 6.03 8.00 10.56 13.16 16.00 18.90 21.49 24.18 26.84 21.9%
Total 60.71 85.02 119.92 167.87 233.28 322.31 444.65 580.69 742.17 924.56 1,114.11 1,334.37 1,584.93 28.3%
107 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 108
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.9.2 Market Size & Forecast, by Application
TABLE 27 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 10.39 14.52 20.44 28.56 39.60 54.60 75.17 97.96 124.94 155.33 186.78 223.24 264.61 28.1%
Traits Screening 2.91 4.05 5.66 7.86 10.84 14.86 20.34 26.36 33.42 41.31 49.39 58.69 69.17 27.3%
Genetic Disease Carrier Status 22.43 31.29 43.94 61.26 84.77 116.64 160.23 208.38 265.21 329.00 394.79 470.86 556.93 27.8%
New Baby Screening 8.46 11.95 16.99 23.98 33.59 46.79 65.07 85.66 110.37 138.60 168.37 203.29 243.41 29.4%
Health And Wellness-
Predisposition/Risk/Tendency 16.50 23.21 32.88 46.21 64.47 89.42 123.84 162.33 208.22 260.32 314.78 378.29 450.81 28.8%
Total 60.71 85.02 119.92 167.87 233.28 322.31 444.65 580.69 742.17 924.56 1,114.11 1,334.37 1,584.93 28.3%
108 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 109
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.9.3 Market Size & Forecast, by Product
TABLE 28 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 34.78 49.04 69.63 98.14 137.29 190.96 265.20 348.67 448.61 562.61 682.50 822.91 983.99 29.2%
Equipment 17.33 24.04 33.58 46.55 64.05 87.64 119.72 154.83 195.95 241.73 288.45 342.11 402.39 27.1%
Software & Services 8.59 11.94 16.71 23.19 31.94 43.72 59.73 77.20 97.61 120.22 143.16 169.35 198.55 26.9%
Total 60.71 85.02 119.92 167.87 233.28 322.31 444.65 580.69 742.17 924.56 1,114.11 1,334.37 1,584.93 28.3%
109 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 110
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.9.4 Market Size & Forecast, by End User
TABLE 29 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 27.95 39.02 54.86 76.56 106.04 146.05 200.84 261.45 333.08 413.61 496.81 593.13 702.25 27.9%
Diagnostic Laboratories 21.68 30.64 43.63 61.65 86.47 120.60 167.94 221.39 285.61 359.15 436.86 528.15 633.22 29.5%
Others 11.08 15.36 21.43 29.67 40.76 55.66 75.87 97.86 123.48 151.80 180.44 213.10 249.46 26.7%
Total 60.71 85.02 119.92 167.87 233.28 322.31 444.65 580.69 742.17 924.56 1,114.11 1,334.37 1,584.93 28.3%
110 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 111
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.10 Rest of Asia Pacific
6.10.1 Market Size & Forecast, by Technology
TABLE 30 GENETIC TESTING MARKET SHARE, BY TECHNOLOGY-2020-2032 (USD MILLION)
Technology 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Next Generation
Sequencing 182.74 261.42 374.35 528.80 734.17 1,006.71 1,363.47 1,733.47 2,135.88 2,533.93 2,865.92 3,163.64 3,381.99 22.9%
Array Technology 108.91 154.74 220.09 308.79 425.81 579.94 780.15 985.14 1,205.62 1,420.64 1,595.90 1,749.77 1,857.89 22.1%
PCR-Based Testing 55.49 79.82 114.94 163.27 227.95 314.33 428.10 547.33 678.16 809.05 920.18 1,021.46 1,098.08 23.6%
FISH 23.25 32.97 46.80 65.54 90.20 122.60 164.60 207.43 253.35 297.94 334.03 365.51 387.33 21.8%
Others 13.16 18.30 25.46 34.88 46.90 62.18 81.30 99.60 118.01 134.33 145.43 153.27 155.97 18.1%
Total 383.55 547.27 781.63 1,101.28 1,525.03 2,085.76 2,817.62 3,572.97 4,391.02 5,195.90 5,861.46 6,453.65 6,881.25 22.6%
111 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 112
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.10.2 Market Size & Forecast, by Application
TABLE 31 GENETIC TESTING MARKET SHARE, BY APPLICATION-2020-2032 (USD MILLION)
Application 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Ancestry & Ethnicity 66.34 94.46 134.63 189.29 261.59 357.02 481.30 609.06 746.95 882.03 992.95 1,090.99 1,160.86 22.3%
Traits Screening 19.13 27.09 38.39 53.66 73.72 100.04 134.08 168.70 205.69 241.49 270.29 295.26 312.36 21.6%
Genetic Disease Carrier Status 144.75 205.67 292.52 410.41 565.95 770.80 1,036.89 1,309.35 1,602.39 1,888.17 2,121.10 2,325.62 2,469.31 22.1%
New Baby Screening 51.37 73.89 106.39 151.11 210.94 290.84 396.06 506.29 627.24 748.21 850.87 944.41 1,015.12 23.6%
Health And Wellness-
Predisposition/Risk/Tendency 101.95 146.16 209.71 296.81 412.83 567.07 769.29 979.57 1,208.75 1,436.00 1,626.25 1,797.37 1,923.59 23.1%
Total 383.55 547.27 781.63 1,101.28 1,525.03 2,085.76 2,817.62 3,572.97 4,391.02 5,195.90 5,861.46 6,453.65 6,881.25 22.6%
112 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 113
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.10.3 Market Size & Forecast, by Product
TABLE 32 GENETIC TESTING MARKET SHARE, BY PRODUCT-2020-2032 (USD MILLION)
Product 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Consumables 212.54 305.30 438.97 622.63 867.99 1,195.10 1,625.26 2,074.79 2,566.93 3,057.83 3,472.65 3,849.15 4,131.71 23.4%
Equipment 115.01 162.51 229.84 320.68 439.74 595.57 796.70 1,000.44 1,217.51 1,426.65 1,593.71 1,737.63 1,834.71 21.4%
Software & Services 56.00 79.46 112.83 157.98 217.30 295.10 395.66 497.74 606.58 711.42 795.09 866.87 914.83 21.5%
Total 383.55 547.27 781.63 1,101.28 1,525.03 2,085.76 2,817.62 3,572.97 4,391.02 5,195.90 5,861.46 6,453.65 6,881.25 22.6%
113 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 114
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
6.10.4 Market Size & Forecast, by End User
TABLE 33 GENETIC TESTING MARKET SHARE, BY END USER-2020-2032 (USD MILLION)
End User 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 CAGR
Hospitals & Clinics 178.31 253.60 361.05 507.08 699.94 954.24 1,284.94 1,624.20 1,989.68 2,346.86 2,639.01 2,896.34 3,078.37 22.2%
Diagnostic Laboratories 133.16 191.78 276.49 393.23 549.65 758.82 1,034.73 1,324.46 1,643.02 1,962.47 2,234.68 2,483.60 2,673.07 23.7%
Others 72.09 101.88 144.09 200.98 275.44 372.70 497.96 624.32 758.33 886.57 987.77 1,073.71 1,129.81 21.1%
Total 383.55 547.27 781.63 1,101.28 1,525.03 2,085.76 2,817.62 3,572.97 4,391.02 5,195.90 5,861.46 6,453.65 6,881.25 22.6%
114 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 115
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7 COMPANY PROFILES
7.1 F. Hoffmann-La Roche Ltd
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of
oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008.
Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of
diagnostic-related sales, Roche, a biotechnology firm, specializes in the development of drugs and diagnostics aimed at addressing major
diseases. The company focuses on providing medications for cancer, autoimmune conditions, central nervous system disorders,
ophthalmological issues, infectious diseases, and respiratory ailments. Additionally, Roche offers in vitro diagnostics, cancer diagnostics
based on tissue samples, and solutions for diabetes management. The company engages in research to discover innovative approaches
for the prevention, diagnosis, and treatment of diseases. Roche distributes its products and services to hospitals, healthcare
professionals, commercial laboratories, researchers, and pharmacists. Operating globally through subsidiaries and partners, the
company is headquartered in Basel, Switzerland.
Pharmaceuticals Division: Roche's Pharmaceuticals division is a key driver of the company's business and focuses on the research,
development, manufacturing, and marketing of prescription drugs across various therapeutic areas. Roche is particularly known for its
contributions to oncology, immunology, infectious diseases, neuroscience, and other medical fields.
Diagnostics Division: Roche is a major player in the global diagnostics market. The Diagnostics division is involved in developing and
producing in vitro diagnostic tests and equipment for medical laboratories, healthcare professionals, and patients. This includes a broad
range of products for clinical chemistry, molecular diagnostics, tissue diagnostics, and blood screening.
115 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 116
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.1.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name F. Hoffmann-La Roche Ltd
2 Inception 1896
Headquartered Grenzacherstrasse 124
4070 Basel
3
Switzerland
+41 061
Logo
4
5 Website www.roche.com
Key ProductTypes Accutane/RoAccutane
6
Boniva Bonviva
116 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 117
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Cymevene
Erivedge
Gazyva
MabThera
Protropin
Rituxan
Rohypnol
Toradol
Vesanoid
Xolair
Zenapax
Key Regions of Sales America
Asia Pacific
7 Europe
Middle East & Africa
Switzerland
117 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 118
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
8 Ownership Status Public
9 No.of Employees ~ 103,613
10 Total Revenue 2022 65,356 m USD
7.1.2 Key Executives
Name Designation
Severin Schwan Chairman
Matt Sause Director; Chief Executive Officer - Roche Diagnostics
Thomas Schinecker Chief Executive Officer
Cristina A. Wilbur Chief People Officer
Levi Garraway Head - Global Product Development; Chief Medical Officer
Jürgen Steinemann Board of Director
Olivier Verscheure Board of Director
118 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 119
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.1.3 Financial Overview
Year 2021 2022 2023
Revenue 68,710 66,291 65,356
(USD Million)
7.1.4 Product Portfolio
Information
Roche firm commitment to research and development allows us
to offer a robust end-to-end portfolio that is uniquely designed to
address the real-world needs of laboratories, their customers,
and the patients they serve.
Molecular diagnostics cobas® Influenza A/B & RSV UC Test
cobas® SARS-CoV-2
cobas® SARS-CoV-2 Test
cobas® eplex Blood Culture Identification
119 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 120
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
cobas® SARS-CoV-2 & Influenza A/B
cobas® eplex Blood Culture Identification
cobas® Synergy Software
cobas® eplex Blood Culture Identification
cobas® eplex Respiratory Pathogen
UC-TIB-AdV
UC-TIB-HSV/VZV
cobas® Cdiff
7.1.5 Key Strategic Developments
Date Development
Roche (ROG.S), opens new tab agreed to take over unlisted
obesity drug developer Carmot Therapeutics (CRMO.O), opens
December 2023 new tab for $2.7 billion upfront, joining a list of contestants
seeking to challenge the dominant makers of weight-loss drugs
Novo Nordisk and Eli Lilly.
120 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 121
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.2 Agilent Technologies Inc
Agilent Technologies, Inc (Agilent) is a leading provider of analyzing instruments, reagents, and consumables for laboratory processes,
complemented by software and services. The company's primary focus is on scientific research, patient diagnostics, and safety testing
within water, food, and pharmaceutical sectors. Agilent's diverse product portfolio spans mass spectrometry, microarray solutions, flow
cytometry, and vacuum technologies, among others. Serving various industries such as contract research organizations, contract
manufacturing organizations, pharmaceuticals, diagnostics, applied materials, and chemicals, Agilent has a global presence with sales
offices, logistics centers, R&D facilities, and business operations. The company commercializes its products through a diverse network
of sales agents, distributors, resellers, manufacturers' representatives, and electronic commerce channels. Headquartered in Santa
Clara, California, Agilent Technologies operates in three business segments: Life Sciences and Applied Markets, Agilent CrossLab, and
Diagnostics and Genomics. The company places a strong emphasis on research and development, investing significantly in innovative
products and services to maintain its competitive edge. With R&D facilities across multiple countries, Agilent reported $481 million in
R&D expenses in FY2023, constituting 7% of its total revenue. Established in 1999, Agilent continues to play a pivotal role in advancing
analytical technologies for various industries.
Life Sciences and Applied Markets: This segment focuses on providing application-focused solutions, including instruments and
software. Its offerings enable customers to identify, quantify, and analyze the physical and biological properties of substances and
products. Major products within this segment include liquid and gas chromatography systems and components, chromatography mass
spectrometry systems, atomic absorption instruments, hematoxylin & eosin, inductively coupled plasma mass spectrometry
instruments, lab supplies for chromatography & spectroscopy, dissolution testing, vacuum pumps, and measurement technologies.
121 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 122
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Agilent CrossLab: This segment offers a range of laboratory services and consumables, facilitating customers in clinical and life sciences
research areas. It allows for the cross-examination of samples at the molecular level, providing comprehensive support to researchers
and scientists.
Diagnostics and Genomics: This segment is dedicated to products and services related to diagnostics and genomics. It plays a vital role
in advancing technologies for clinical and research purposes, contributing to the understanding and analysis of genetic information.
7.2.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Agilent Technologies Inc
2 Inception 1999
Headquartered 5301 Stevens Creek Blvd, Santa Clara, California,
3 95051
United States of America
122 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 123
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Logo
4
5 Website www.agilent.com
Key Product Types Diagnostics & Genomics
Chemical Analysis
Life Sciences
Environmental & Forensics
Food Safety
6 Pharmaceutical
Cancer Research
Pathology
Agriculture
Clinical Diagnostics
Biopharma
7 Key Regions of Sales The United States
123 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 124
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Other Countries
8 Ownership Status Public
9 No.of Employees ~ 18,100
10 Total Revenue 2022 6,833 m USD
7.2.2 Key Executives
Name Designation
Mike McMullen President and Chief Executive Officer
Henrik Ancher-Jensen Senior Vice President
Allison Ballmer Senior Vice President
Philip Binns Senior Vice President
Mala Anand Board of Director
124 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 125
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.2.3 Financial Overview
Year 2021 2022 2023
Revenue 6,319 6,848 6,833
(USD Million)
7.2.4 Product Portfolio
System Information
With newly added Polymer Standards Services (PSS) products,
Agilent now offers the largest single-vendor solution for all your
GPC/SEC analyses, from ambient to high-temperature and
aqueous to organic, generating accurate, reliable data for
Streamlined GPC/SEC Solutions Unlock Vast Potential for macromolecular characterization. Instruments, columns,
Macromolecular Analyses standards, and software with proven compatibility enable the
smoothest execution of GPC/SEC workflows. If challenges arise,
Agilent also offers tailored expert services. The sky’s the limit
with the largest portfolio for your largest molecules—Agilent
InfinityLab GPC/SEC Solutions.
125 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 126
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Theoretically, nuclear fusion has the potential to generate clean
Nuclear Fusion: A Vision for Clean Energy
energy while mitigating the effects of global warming
It is estimated that more than 75% of the 8.3 billion metric tons
of plastic produced over the last 65 years have turned into waste,
of which up to 13 million metric tons end up in our oceans every
Mitigating Plastic Pollution While Regenerating Our Oceans
year.1, 2 Organizations like ULUU are trying to solve the growing
issue of plastic pollution by prototyping alternative materials to
market.
Data integrity is paramount in today's digital world. Presenting
uncompromised results and maintaining compliance with the
latest regulations and standards—including those issued by the
pharmaceutical, environmental and food regulatory bodies (e.g.,
FDA, ISO, USDA, Annex 11)—is a necessity. The traditional
Ensure Data Integrity in Laboratories
approaches to laboratory data integrity are not enough to meet
today's increased scrutiny of computerized systems and the
terabytes of data they produce. To successfully present your
results, you must be prepared to prove that your data have not
been compromised—and that can be a challenge.
126 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 127
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.3 Abbott Laboratories
Abbott Laboratories (Abbott), a global healthcare company headquartered in Abbott Park, Illinois, specializes in a diverse portfolio of
healthcare products ranging from branded generic pharmaceuticals to diagnostic systems and tests, and pediatric and adult nutritional
products. Additionally, Abbott offers an array of medical devices, including those for heart failure, electrophysiology, rhythm
management, vascular and structural heart conditions, and neuromodulation. The company's reach extends across North America, Latin
America, Europe, Asia-Pacific, the Middle East, and Africa, with research and development (R&D) facilities spanning multiple countries
including the US, Colombia, India, Singapore, Spain, and the UK.
Abbott's research and development efforts are substantial, with a significant investment in enhancing existing products and processes,
as well as developing new solutions to address evolving healthcare needs. In the fiscal year 2023, Abbott allocated US$2,741 million to
R&D activities, representing 6.8% of its revenue. This commitment underscores Abbott's dedication to innovation and improving
patient outcomes across its diverse product portfolio.
Business Segments:
Diagnostic Products: Offers diagnostic systems and tests to various healthcare settings including hospitals, laboratories, physician
offices, and clinics. Products include laboratory systems, molecular diagnostic systems, genomic-based tests, point-of-care systems,
rapid diagnostic systems, and informatics and automation solutions.
Established Pharmaceutical Products: Provides branded generic drugs globally, addressing a range of therapeutic areas including
gastroenterology, women's health, cardiovascular, metabolic, pain management, central nervous system, respiratory, and vaccines.
127 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 128
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Medical Devices: Offers a wide range of devices for cardiovascular diseases (rhythm management, heart failure, electrophysiology,
vascular and structural heart devices), chronic pain management and movement disorders (neuromodulation devices), and diabetes
care products.
Nutritional Products: Offers pediatric and adult nutritional products catering to the nutritional needs of individuals with chronic
illnesses. Products include infant formula, follow-on formula, adult nutritional supplements, enteral feeding products, and dietary
supplements.
7.3.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Abbott Laboratories
2 Inception 1888
Headquartered 100 Abbott Park Road, Abbot Park, Illinois, 60064-
3 3500
United States of America
128 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 129
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Logo
4
5 Website www.abbott.com
Key ProductTypes Cardiovascular
Diabetes Care
Diagnostics
6 Neuromodulation
Nutrition
Medicines
Branded Generic Pharmaceuticals
Key Regions of Sales Asia Pacific
Greater China
7 Europe
Middle East And South Africa
The Americas
129 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 130
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
8 Ownership Status Public
9 No.of Employees ~
10 Total Revenue 2022 40,109 m USD
7.3.2 Key Executives
Name Designation
ROBERT B. FORD Chairman and Chief Executive Officer
HUBERT L. ALLEN Executive Vice President, General Counsel and Secretary
LISA D. EARNHARDT Executive Vice President and Group President, Medical Devices
ROBERT E. FUNCK, JR. Executive Vice President, Finance
JOSEPH MANNING Executive Vice President, Nutritional Products
MARY K. MORELAND Executive Vice President, Human Resources
LOUIS H. MORRONE Executive Vice President, Core Diagnostics
130 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 131
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Executive Vice President and Group President, Established
DANIEL SALVADORI
Pharmaceuticals and Nutritional Products
ANDREA F. WAINER Executive Vice President, Rapid and Molecular Diagnostics
JARED L. WATKIN Executive Vice President, Diabetes Care
PHIL BOUDREAU Senior Vice President, Finance, and Chief Financial Officer
CHRISTOPHER J. CALAMARI Senior Vice President, U.S. Nutrition
Senior Vice President, Business and Technology Services and
SABINA EWING
Chief Information Officer
Senior Vice President, Quality Assurance, Regulatory and
J. SCOTT HOUSE
Engineering Services
Senior Vice President, Emerging Markets Established
SAMMY G. KARAM
Pharmaceuticals
SCOTT M. LEINENWEBER Senior Vice President, Licensing, Acquisitions and Ventures
FERNANDO MATEUS Senior Vice President, International Nutrition
131 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 132
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Senior Vice President, Commercial Operations and Marketing,
CHRIS J. SCOGGINS
Diabetes Care
JULIE TYLER Senior Vice President, Vascular
Senior Vice President, Established Pharmaceuticals, Latin
ALEJANDRO WELLISCH
America
RANDEL WOODGRIFT Senior Vice President, Cardiac Rhythm Management
SANDRA LESENFANTS Senior Vice President, Structural Heart
URI YARON Senior Vice President, Electrophysiology
7.3.3 Financial Overview
Year 2021 2022 2023
Revenue 43,075 43,653 40,109
(USD Million)
132 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 133
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.3.4 Product Portfolio
Information
AneuVysion: AneuVysion is a FDA-cleared product for the rapid
detection of aneusomy (an abnormal number of chromosomes)
in amniotic fluid samples. It is a fluorescence in situ hybridization
(FISH) test that can detect trisomies (3 copies of a chromosome
instead of the usual 2) and monosomies (1 copy of a chromosome
VYSIS FISH GENETICS
instead of the usual 2) for chromosomes 13, 18, 21, and X and Y.
DNA FISH probes: Abbott Molecular Diagnostics offers an
expansive line of DNA FISH probes for preimplantation, prenatal,
and postnatal genetic testing research. These probes can be used
to identify a wide range of chromosomal abnormalities.
133 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 134
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.3.5 Key Strategic Developments
Date Development
Abbott (NYSE: ABT) announced that the U.S. Food and Drug
Administration (FDA) has approved the Esprit™ BTK Everolimus
Eluting Resorbable Scaffold System (Esprit BTK System), a
breakthrough innovation for people with chronic limb-
April 2024
threatening ischemia (CLTI) below-the-knee (BTK). The Esprit
BTK System is designed to keep arteries open and deliver a drug
(Everolimus) to support vessel healing prior to completely
dissolving.
Abbott announced that the U.S. Food and Drug Administration
(FDA) has approved the company's first-of-its-kind TriClip™
transcatheter edge-to-edge repair (TEER) system that's
April 2024 specifically designed for the treatment of tricuspid regurgitation
(TR), or a leaky tricuspid valve. This approval follows the recent
recommendation of the Circulatory System Devices Panel of the
Medical Devices Advisory Committee for the FDA, whose vote
134 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 135
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
confirmed 13 to 1, with 0 abstention that the benefits of TriClip
outweighed the risks.
Abbott announced it has completed the acquisition of
Cardiovascular Systems, Inc. (CSI), a medical device company
April 2023
with an innovative atherectomy system used in treating
peripheral and coronary artery disease.
135 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 136
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.4 Illumina Inc
Illumina Inc. is a leading provider of genomic sequencing and array-based solutions, catering to molecular diagnostics, translational
and consumer genomics, and cancer research sectors. The company's extensive portfolio includes sequencing kits, reagents, tools,
systems, microarrays, and molecular biology reagents. Illumina serves a broad spectrum of clients, including pharmaceutical
companies, academic institutions, genomic research centers, biotechnology firms, and clinical research organizations, operating
globally through direct sales and distribution channels. Headquartered in San Diego, California, Illumina's business segments comprise
Core Illumina and GRAIL. The Core Illumina segment offers a range of consumables and instruments for genetic analysis, including
array-based genotyping consumables and DNA sequencing systems. Meanwhile, GRAIL focuses on innovative cancer detection
solutions. Illumina's research and development division is dedicated to enhancing existing products and developing new techno logies,
leveraging sequencing by synthesis (SBS), next-generation sequencing (NGS), and BeadArray technology platforms. With substantial
investments in R&D and a robust patent portfolio, Illumina remains a key player in the genomics industry, poised to address evolving
market demands and technological advancements.
Business Segments:
Core Illumina: This segment focuses on providing a wide array of consumables and instruments for genetic analysis. It includes products
such as array-based genotyping consumables, next-generation sequencing (NGS) assays, library preparation kits, cluster generation
and sequencing reagents, microarrays, extended RAS panel, and accessory products. The instruments offered by Core Illumina
encompass DNA sequencing and array-based systems and technologies for various DNA and RNA analyses, including copy number
variation (CNV) analysis, gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and methylation analysis.
Notable products within this segment include sequencing systems like MiniSeq, MiSeq, iSeq, NextSeq, HiSeq, and NovaSeq systems.
136 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 137
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
GRAIL: This segment is dedicated to developing innovative cancer detection solutions. While the specifics of GRAIL's products and
services are not provided in detail, it can be inferred that this segment focuses on advancing technologies and methodologies for early
cancer detection, possibly utilizing Illumina's expertise in genomic sequencing and analysis.
7.4.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Illumina Inc
2 Inception 1998
Headquartered 5200 Illumina Way, San Diego, California, 92122-
3 4616
United States of America
4 Logo
5 Website www.illumina.com
137 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 138
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Key ProductTypes Instruments
Kits & Reagents
Selection Tools
6
Software & Analysis
Services
Popular Products
Key Regions of Sales The Americas
Asia-Pacific
7
Europe
The Middle East & Africa
8 Ownership Status Public
9 No.of Employees ~ 10,590
10 Total Revenue 2022 4,504 m USD
138 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 139
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.4.2 Key Executives
Name Designation
Stephen P. MacMillan Chair of the Board
Jacob Thaysen Chief Executive Officer
Charles Dadswell General Counsel
Steve Barnard Chief Technology Officer
Nicole Berry Head of Region—Americas
Ankur Dhingra Chief Financial Officer
Pat Leckman Chief People Officer
Kevin Pegels Chief of Global Operations
Carissa Rollins Chief Information Officer
Salli Schwartz Vice President of Investor Relations
Bas Verhoef Head of Region—Europe, Interim Chief Commercial Officer
139 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 140
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Jakob Wedel Chief Strategy and Corporate Development Officer
Gretchen Weightman Head of Region—Asia Pacific, Middle East, and Africa
Jenny Zheng Head of Region—Greater China
140 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 141
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.4.3 Financial Overview
Year 2021 2022 2023
Revenue 4,526 4,584 4,504
(USD Million)
7.4.4 Product Portfolio
System Information
NextSeq 2000 Sequencing System
Systems for Research NovaSeq 6000 Sequencing System
NovaSeq 550 Sequencing System
iScan System
Systems for Research
NextSeq 550 System
TruSight Oncology 500
Library Prep Kits
AmpliSeq
141 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 142
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Illumina DNA Prep
NovaSeq 6000 Reagents
Sequencing Reagents MiSeq Reagents
NextSeq 1000/2000 Reagents
Infinium MethylationEPIC v2.0 Kit
Microarray Kits Infinium Global Screening Array-24 Kit
Infinium Global Diversity Array with Enhanced PGx
NovaSeq X Series
Illumina Complete Long Reads, Human
Innovations from Illumina
Illumina DNA Prep with Exome 2.0 Plus Enrichment
Molecular Biology Reagents
NovaSeq 6000Dx Reagents
Products for in vitro diagnostic use Illumina DNA Prep with Enrichment Dx
VeriSeq NIPT
142 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 143
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.4.5 Key Strategic Developments
Date Development
Illumina Inc., a global leader in DNA sequencing and array-based
technologies, announced a new generation of its distributed
liquid biopsy assay for genomic profiling. The new TruSight™
November 2023 Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay
that enables noninvasive comprehensive genomic profiling (CGP)
of circulating tumor DNA (ctDNA) from blood when tissue testing
is not available, or to complement tissue-based testing.
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing
and array-based technologies, announced a strategic research
collaboration with AstraZeneca, a global, science-led
biopharmaceutical company, to accelerate drug target discovery
October 2022
by combining their strengths in artificial intelligence (AI) based
genome interpretation and genomic analysis techniques along
with industry expertise. The collaboration will evaluate whether
a combined framework of these technologies can increase the
143 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 144
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
yield and confidence of target discovery to find promising drugs
based on human omics insights.
Illumina, Inc., received a decision from the European Commission
prohibiting the company's acquisition of GRAIL. The company is
reviewing the Commission's order and intends to appeal the
September 2022
decision. The EC decision follows last week's ruling by US Federal
Trade Commission judge in favor of Illumina's acquisition of
GRAIL.
Illumina, Inc., a global leader in DNA sequencing and array-based
technologies, announced the launch of the NovaSeq™ X Series
(NovaSeq X and NovaSeq X Plus), new production-scale
sequencers that will push the limits of what is possible with
genomic medicine, enabling faster, more powerful, and more
September 2022
sustainable sequencing. Using revolutionary new technology,
NovaSeq X Plus can generate more than 20,000 whole genomes
per year – 2.5 times the throughput of prior sequencers – greatly
accelerating genomic discovery and clinical insights, to
understand disease and ultimately transform patient lives.
144 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 145
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.5 Thermos Fisher Scientific Inc
Thermo Fisher Scientific Inc. is a prominent player in the analytical instruments and life sciences solutions industry, offering a wide
range of products and services including laboratory supplies, equipment, instruments, clinical tools, and diagnostics. Its extensive
portfolio caters to various sectors such as industrial and applied sciences, biotechnology, pharmaceuticals, healthcare, food & beverage,
and forensics. Operating through direct sales professionals, industry-specific catalogs, e-commerce capabilities, and supply-chain
management services, Thermo Fisher is headquartered in Waltham, Massachusetts, USA.
Business Segments:
Analytical Instruments: This segment offers instruments, consumables, software, and services primarily through Chromatography and
Mass Spectrometry; Chemical Analysis; and Electron Microscopy divisions. These products find applications in pharmaceutical,
biotechnology, academics, government, environmental, and other research and industrial markets.
Laboratory Products and Biopharma Services: Providing an array of products and services for laboratories, this segment includes
divisions such as Laboratory Products, Laboratory Chemicals, Research and Safety Market Channel, Pharma Services, and Clinical
Research. The offerings cover a wide range of laboratory equipment, chemicals, solvents, reagents, safety equipment, and pharma
services for various industries.
Life Sciences Solutions: Comprising divisions like Biosciences, Genetic Sciences, and BioProduction, this segment offers reag ents,
instruments, and consumables for biological and medical research, drug and vaccine development, and disease diagnosis. These
solutions cater to research, clinical, healthcare, and applied markets.
145 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 146
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Specialty Diagnostics: Operating through businesses like Clinical Diagnostics, Microbiology, ImmunoDiagnostics, Transplant
Diagnostics, and Healthcare Market Channel, this segment provides diagnostic test kits, reagents, culture media, instruments, and
related products to healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.
Thermo Fisher's R&D efforts focus on product development and enhancement, with significant investments made in research services
related to pharmaceuticals, biologics, clinical development, and analytical services. In FY2023, the company allocated US$1,337 million
towards R&D activities, accounting for 3.1% of its revenue.
7.5.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Thermo Fisher Scientific Inc
2 Inception 1956
Headquartered 168 Third Avenue, Waltham, Massachusetts, 02451
3
United States of America
146 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 147
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Logo
4
5 Website www.thermofisher.com
Key ProductTypes Analytical Instruments
Laboratory Supply Chain Programs and eCommerce
Laboratory Equipment
Lab Services
6
Specialty Diagnostics
Life Sciences
Pharma Services
CDMO
Key Regions of Sales The Americas
7 APAC
EMEA
8 Ownership Status Public
147 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 148
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
9 No.of Employees ~ 122,000
10 Total Revenue 2022 42,857 m USD
7.5.2 Key Executives
Name Designation
Marc N. Casper Chairman
Stephen Williamson Senior Vice President and Chief Financial Officer
Michel Lagarde Executive Vice President and Chief Operating Officer
Lisa P. Britt Senior Vice President and Chief Human Resources Officer
Sandy Pound Vice President and Chief Communications Officer
Aditya Joshi Vice President and Chief Strategy Officer
Ryan Snyder Senior Vice President and Chief Information Officer
Karen E. Nelson Chief Scientific Officer
148 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 149
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Alan Sachs Chief Medical Officer
Lisa Witte Senior Vice President and President, Customer Channels
Konrad Bauer Senior Vice President, Global Business Services
Michael A. Boxer Senior Vice President and General Counsel
Daniella Cramp Senior Vice President and President, BioProduction
Executive Vice President and President, Laboratory Products and
Frederick M. Lowery
BioProduction
Jim Meyer Vice President, Financial Operations
Paul Parker Senior Vice President, Strategy and Corporate Development
Gianluca Pettiti Executive Vice President
Mike Shafer Executive Vice President and President, Biopharma Services
Daniel P. Shine Senior Vice President and President, Analytical Instruments
Mark Smedley Senior Vice President and President, Regions
149 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 150
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
John Sos Senior Vice President and President, Specialty Diagnostics
Richard Spoor Senior Vice President and President, Laboratory Products
Sebastian Pacios Senior Vice President and President, Clinical Research
7.5.3 Financial Overview
Year 2021 2022 2023
Revenue 39,211 44,915 42,857
(USD Million)
7.5.4 Product Portfolio
System Information
Thermo Fisher provides polymerase chain reaction (PCR)
PCR Instruments and Reagents
instruments and reagents used in DNA amplification and analysis.
150 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 151
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
These products are crucial for various genetic testing
applications, such as genotyping and gene expression analysis.
Thermo Fisher offers NGS systems like the Ion Torrent
sequencers, which enable high-throughput sequencing of DNA
Next-Generation Sequencing (NGS) Systems
and RNA. These systems are used in research, clinical diagnostics,
and other genetic testing applications.
Thermo Fisher provides software solutions for analyzing genetic
data generated by their instruments. These software packages
Genetic Analysis Software
facilitate data interpretation, variant calling, and other
bioinformatics tasks essential for genetic testing.
Thermo Fisher offers a variety of sample preparation kits for
isolating and purifying nucleic acids from different sample types.
Sample Preparation Kits
These kits are crucial for preparing DNA and RNA samples for
downstream genetic analysis.
Thermo Fisher develops and markets a wide range of genetic
testing assays for detecting specific genetic variants associated
Genetic Testing Assays
with diseases, pharmacogenomics, and other applications. These
assays are often used in clinical diagnostics and research settings.
151 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 152
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Thermo Fisher provides polymerase chain reaction (PCR)
instruments and reagents used in DNA amplification and analysis.
PCR Instruments and Reagents
These products are crucial for various genetic testing
applications, such as genotyping and gene expression analysis.
Thermo Fisher offers NGS systems like the Ion Torrent
sequencers, which enable high-throughput sequencing of DNA
Next-Generation Sequencing (NGS) Systems
and RNA. These systems are used in research, clinical diagnostics,
and other genetic testing applications.
Thermo Fisher provides software solutions for analyzing genetic
data generated by their instruments. These software packages
Genetic Analysis Software
facilitate data interpretation, variant calling, and other
bioinformatics tasks essential for genetic testing.
Thermo Fisher offers a variety of sample preparation kits for
isolating and purifying nucleic acids from different sample types.
Sample Preparation Kits
These kits are crucial for preparing DNA and RNA samples for
downstream genetic analysis.
Thermo Fisher develops and markets a wide range of genetic
Genetic Testing Assays
testing assays for detecting specific genetic variants associated
152 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 153
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
with diseases, pharmacogenomics, and other applications. These
assays are often used in clinical diagnostics and research settings.
7.5.5 Key Strategic Developments
Date Development
Thermo Fisher Scientific Inc. (“Thermo Fisher”), the world leader
in serving science, and Olink Holding AB (publ) (“Olink”), a
leading provider of next-generation proteomics solutions, today
announced that their respective boards of directors have
approved Thermo Fisher’s proposal to acquire Olink for $26.00
per common share in cash, representing $26.00 per American
October 2023 Depositary Share (ADS) in cash. This represents a premium of
approximately 74% to the closing price of Olink’s American
Depositary Shares that trade on NASDAQ on October 16, 2023, the
last trading day prior to the announcement of the transaction.
Thermo Fisher will commence a tender offer to acquire all of the
outstanding Olink common shares and all of the American
Depositary Shares. The transaction values Olink at approximately
153 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 154
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
$3.1 billion which includes net cash of approximately $143
million.
Thermo Fisher Scientific Inc., the world leader in serving science,
and PeproTech, Inc., a leading developer and manufacturer of
January 2022 recombinant proteins, announced that Thermo Fisher completed
its acquisition of PeproTech on December 30, 2021 for a total cash
purchase price of approximately $1.85 billion.
Thermo Fisher Scientific Inc., the world leader in serving science,
announced that it has completed its acquisition of PPD, Inc.
December 2021
(Nasdaq: PPD), a leading global provider of clinical research
services to the biopharma and biotech industry, for $17.4 billion.
154 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 155
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.6 CSL Ltd
CSL Ltd (CSL) stands at the forefront of biopharmaceutical innovation, with a rich legacy dating back to its inception in 1916.
Headquartered in Parkville, Victoria, Australia, the company has established itself as a global leader in discovering, developing,
manufacturing, and distributing a diverse range of biopharmaceuticals and related products. CSL's extensive portfolio encompasses
plasma-derived therapies tailored for various medical conditions, including hemophilia, hereditary angioedema, von Willebrand
disease, immune deficiencies, neurological disorders, and respiratory diseases. Additionally, CSL provides critical products for
preventing hemolytic disease in newborns, managing infections in transplant recipients, and treating specific infections in trauma and
burn victims.
With operations spanning across Australia, Germany, Switzerland, the US, the UK, and beyond, CSL serves a broad international market.
The company's offerings extend beyond plasma-derived treatments, encompassing vaccines, anti-venoms, and pharmaceutical
products sourced from various manufacturers. CSL operates through three primary segments: CSL Behring, Vifor, and Seqirus, each
focusing on specific areas of research, development, and distribution.
At its core, CSL remains committed to advancing medical science through rigorous research and development efforts. Collaborating
with academic institutions and corporate partners, CSL continually explores new frontiers in biotechnology, striving to develop
groundbreaking therapies and vaccines to address unmet medical needs. Through its unwavering dedication to scientific advancement
and global healthcare, CSL continues to make significant strides in improving patient outcomes and enhancing quality of life worldwide.
Business segments:
CSL Behring: This segment focuses on the research, development, manufacturing, marketing, and distribution of plasma protein
biotherapies. CSL Behring specializes in therapies to treat and prevent serious medical conditions such as hemophilia, hereditary
155 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 156
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
angioedema, immune deficiencies, and neurological disorders. The segment's portfolio includes immunoglobulins, coagulation factors,
albumin, and specialty products. CSL Behring is committed to advancing patient care through innovative treatments and therapies
derived from plasma proteins.
Vifor: The Vifor segment is involved in the development, manufacture, and commercialization of pharmaceutical products, primarily
focused on treating iron deficiency and related disorders. This segment's portfolio includes a range of iron replacement therapies,
including intravenous and oral formulations. Vifor aims to address significant unmet medical needs in the field of iron deficiency and
improve patient outcomes through effective treatments.
Seqirus: Seqirus specializes in the development, production, and distribution of influenza vaccines and related products. As a global
leader in influenza prevention, Seqirus plays a critical role in safeguarding public health against seasonal and pandemic inf luenza
outbreaks. The segment's portfolio includes a range of influenza vaccines tailored to different age groups and populations, along with
antiviral medications and adjuvants. Seqirus is dedicated to advancing influenza prevention through research, innovation, and
collaboration with healthcare partners worldwide.
156 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 157
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.6.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name CSL Ltd
2 Inception 1916
Headquartered 45 Poplar Road, Parkville, Melbourne, Victoria, 3052
3
Australia
Logo
4
5 Website www.csl.com
Key ProductTypes Complex biologicals
vaccines
6
plasma and plasma derived therapeutics
biotechnology
157 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 158
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Key Regions of Sales Australia
Germany
7 Switzerland
the US
the UK
8 Ownership Status Public
9 No.of Employees ~ 32,065
10 Total Revenue 2022 13,310 m USD
7.6.2 Key Executives
Name Designation
Paul McKenzie Chief Executive Officer and Managing Director
Greg Boss Executive Vice President, Legal & General Counsel
Hervé Gisserot Senior Vice President and General Manager
158 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 159
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Mark Hill Chief Digital Information Officer
Ken Lim Executive Vice President and Chief Strategy Officer
Joy Linton Chief Financial Officer
Bill Mezzanotte Executive Vice President, Head of Research & Development
Roanne Parry Chief Human Resources Officer
Kate Priestman Chief Corporate & External Affairs Officer
Dave Ross Senior Vice President & General Manager, CSL Seqirus
Andy Schmeltz Executive Vice President, CSL Behring
7.6.3 Financial Overview
Year 2021 2022 2023
Revenue 10,310 10,562 13,310
(USD Million)
159 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 160
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.6.4 Product Portfolio
Information
CSL is a global leader in developing and delivering high quality
medicines that treat people with rare and serious diseases.
Working every day as if people’s lives depend on it, CSL’s R&D
fuels the company’s sustainable growth by advancing world-class
science, technology and collaboration. CSL strong R&D pipeline
utilises its expertise in plasma protein technology, recombinant
protein technology, cell and gene therapy and vaccines
technology to develop and deliver innovative medicines that
Focused on Innovation address unmet medical needs or enhance current treatments in
six Therapeutic Areas - Immunology, Hematology, Respiratory,
Cardiovascular and Metabolic, Nephrology and Transplant and
Vaccines. CSL R&D portfolio focuses on innovation in new
products, improved products and manufacturing expertise
ensuring CSL continued growth.
Product Pipeline:
Immunology
160 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 161
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Hematology
Cardiovascular and Metabolic
Nephrology and Transplant
Respiratory
Vaccines
CSL Vifor
Outlicensed Programs
All TA's
7.6.5 Key Strategic Developments
Date Development
CSL Seqirus, a subsidiary of CSL Limited , and ARS
Pharmaceuticals, Inc. have announced the signing of an exclusive
May 2024
license and distribution agreement to commercialise neffyTM
(adrenaline nasal spray) in Australia and New Zealand.
161 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 162
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
CSL Vifor and Travere Therapeutics, Inc., announced that the
European Commission has granted conditional marketing
authorization (CMA) for FILSPARI (sparsentan) for the treatment
April 2024 of adults with primary IgAN with a urine protein excretion ≥1.0
g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA
is granted for all member states of the European Union, as well as
in Iceland, Liechtenstein and Norway.
In a move to diversify its business, Australian biopharma CSL has
agreed to acquire Vifor Pharma for $11.7 billion. The deal would
December 2021 give CSL—heavily dependent on vaccines and blood plasma
products—Vifor’s attractive kidney disease and iron deficiency
franchises.
162 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 163
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.7 Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc (Bio-Rad) manufactures and distributes life science research and clinical diagnostics products. The company's
product portfolio includes antibodies, autoimmune testing kits, blood typing and antibody detection systems, cell isolation and analysis
tools, and digital PCR, among others. The company serves to various markets including life science research, healthcare, analytical
chemistry, and other markets. Bio-Rad’s products find applications in bioprocess analytics, cell research, gene expression analysis,
immunology, and mutation detection, among others. It markets products through a direct sales force and a network of distributors,
agents, brokers, and resellers worldwide. The company operates in the US, Canada, Latin America, Europe and Asia, among others. Bio-
Rad Laboratories Inc is headquartered in Hercules, California, the US.
Bio-Rad Laboratories Inc (Bio-Rad) is a provider of life science research and clinical diagnostic products. The company offers products
and services to universities and research institutions; other leading diagnostic manufacturers; hospitals, public health and commercial
laboratories; and leading companies in the pharmaceutical, biotechnology, chemical and food industries.
R&D Overview
Bio-Rad's R&D activities are aimed at the development of new products and the enhancement of existing ones. Its R&D team collaborates
with scientific and medical professionals from pharma and bio-pharma companies, universities, hospitals, and medical schools in the
development of new products and applications. Furthermore, it invests regularly in companies that are developing new technologies
that either complement or expand its existing product portfolio. It has a dedicated workforce of 1,110 employees worldwide involved
in its R&D activities.
In FY2023, Bio-Rad spent US$247.4 million on its R&D, which accounted for 9.3% of the company’s total revenue. As of FY2023, it had
over 2,300 US and international patents and numerous trademarks.
163 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 164
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Business Segments
Clinical Diagnostics
Offers test systems, test kits, informatics systems and specialized quality controls to hospital laboratories, reference and transfusion
laboratories, and physician office laboratories.
Major products include autoimmune, serology, BioPlex 2200 multiplex testing, diabetes testing, hemoglobinopathies,
immunohematology, bacteriology, newborn screening, quality control, special chemistry, critical raw materials, remote monitoring and
support, and access virology and antibodies.
Life Science
Develops and manufactures reagents, apparatus and laboratory instruments, and markets them to universities and medical schools,
government agencies, pharmaceutical manufacturers, industrial research organizations, biotechnology researchers, food producers and
food testing laboratories. Its products are used to separate, purify and identify biological materials including proteins, nucleic acids and
bacteria.
Its major products include genomics, antibodies, digital PCR, flow cytometry, transfection, electrophoresis and blotting, imaging
systems and software, bio-plex multiplex immunoassay systems, microplate systems, cell imaging, cell counting, liquid handling and
pipetting, chromatography, protein sample preparation, protein interaction analysis, sample quantitation, SELDI technology, and
general laboratory equipment.
164 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 165
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.7.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Bio-Rad Laboratories Inc
2 Inception 1952
Headquartered 1000 Alfred Nobel Dr, Hercules, California, 94547-
3 1811
United States of America
Logo
4
5 Website www.bio-rad.com
Key ProductTypes Life Science Products
6 Clinical Diagnostics
Molecular Testing
165 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 166
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Food & Beverage Testing
Key Regions of Sales The United States
Canada
Latin America
7
Europe
Asia
Others
8 Ownership Status Public
9 No.of Employees ~ 1952
10 Total Revenue 2022 2,671 m USD
166 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 167
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.7.2 Financial Overview
Year 2021 2022 2023
Revenue 2,923 2,802 2,671
(USD Million)
7.7.3 Product Portfolio
System Information
Genetics has come a long way since Gregor Mendel presented his
work with peas. Genetic principles and related research
techniques are now used throughout biology, and genetics
impacts many aspects of life. Genetics research frequently uses
Genetics model systems, which consist of a well-characterized subset of
organisms. Many Bio-Rad Explorer lab activities also use model
organisms, enabling students to gain hands-on experiences like
those encountered in research laboratories.
DNA Model Kit
167 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 168
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
PV92 PCR Informatics Kit
C. elegans Behavior Kit
Science of Opioid Dependence Kit
Out of the Blue CRISPR and Genotyping Extension Kits
GMO Investigator Kit
pGLO Bacterial Transformation Kit
DNA Barcoding Kits
GMO Investigator Real-Time PCR Starter Kit
Genes in a Bottle Kit
Forensic DNA Fingerprinting Kit
Crime Scene Investigator PCR Basics Kit
Cloning and Sequencing Explorer Series — All Eight Modules
Crime Scene Investigator PCR Basics Real-Time PCR Starter Kit
Build confidence in your life science research and clinical
Molecular Testing Products diagnostics results with molecular testing products that give you
the sensitivity, efficiency, and reliability you need to advance your
168 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 169
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
research and support patients through health crises. With a range
of products and support spanning molecular controls and
standards, through grants and QC data management solutions,
Bio-Rad is here for every step of your journey.
Molecular Controls for Clinical Diagnostics
Verification Panels for Clinical Diagnostics
QC Data Management
COVID-19 Solutions
7.7.4 Key Strategic Developments
Date Development
Bio-Rad Laboratories, Inc. and QIAGEN N.V., announced that the
companies have agreed to settle their patent dispute pending in
July 2023 the U.S. District Court of Delaware pursuant to a global settlement
and patent cross-licensing agreement relating to digital PCR
technology.
169 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 170
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Bio-Rad Laboratories, Inc., a global leader in life science research
and clinical diagnostic products, announced an expanded
portfolio of independent quality controls (QC) products, now
November 2022
including InteliQ and Liquichek compact vials, for the Abbott
Alinity ci-series integrated clinical chemistry and immunoassay
testing instruments.
Bio-Rad Laboratories, Inc., a global leader in life science research
and clinical diagnostic products, announced that it has reached an
agreement to acquire all of the outstanding shares of Curiosity
Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE
August 2022 NewConnect: SCP), a Warsaw, Poland, based developer of
innovative technology solutions for the medical diagnostic and
healthcare markets, for a total consideration of up to $170
million, consisting of approximately $100 million in cash, and up
to $70 million in future milestone payments.
170 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 171
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.8 Myriad Genetics Inc
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular
diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s
product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins
to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s
likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor
agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland,
the UK, Canada, Italy, Germany, Japan, Australia, and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.
Myriad Genetics Inc (Myriad) develops and commercializes molecular diagnostic products for cancer and arthritis. These diagnostic
tests assess the person’s risk for disease development, disease progression and recurrence and guide through treatment decisions. It
provides patient related critical information to physicians, enabling them to diagnose the disease at an early stage or delay the onset of
the disease. It offers these diagnostic tests in three therapeutic areas such as oncology, women’s health, and mental Health. The company
operates through one reportable segment.
R&D Overview
The company’s research and development are focused on therapy area related to oncology, urology, autoimmune, dermatology, mental
health, and women’s health molecular diagnostic.
The company focuses on the development of proprietary DNA sequencing and RNA expression technologies along with its supporting
bioinformatics and robotic technologies.
171 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 172
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
The company has R&D facilities located in Salt Lake City, South San Francisco, Texas, Ohio, in the US and Toronto, Ontario in Canada. In
FY2022, the company has invested US$85.4 million on R&D related activities, which accounted for 12.6% of the company's annual
revenue.
7.8.1 Company Overview
Company at a Glance
Sr.no Parameter Description
1 Company Name Myriad Genetics Inc
2 Inception 1991
Headquartered 322 North 2200 West, Salt Lake City, Utah, 84116
3
United States of America
Logo
4
5 Website www.myriad.com
172 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 173
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Key ProductTypes Molecular Diagnostics
Personalized Medicine
Prognostic Medicine
Companion Diagnostics
Carrier Screen
Pharmacogenomics
Genetic Testing
6 Hereditary Cancer
Prostate Cancer
Breast Cancer
Prenatal Screen
Precision Medicine
Ovarian Cancer
Pancreatic Cancer
Gender Testing
173 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 174
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Key Regions of Sales US
Spain
France
Switzerland
the UK
7 Canada
Italy
Germany
Japan
Australia
Netherlands
8 Ownership Status Public
9 No.of Employees ~ 2,700
10 Total Revenue 2022 753 m USD
174 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 175
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.8.2 Key Executives
Name Designation
Senior Vice President, Transformation and Chief of Staff to the
Maggie Ancona
CEO
Dr. Kevin R. Haas Chief Technology Officer
Scott Leffler Chief Financial Officer
Dr. Dale Muzzey Chief Scientific Officer
Sam Raha Chief Operating Officer
Shereen Solaiman Chief People Officer
Mark S. Verratti Chief Commercial Officer
175 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 176
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
7.8.3 Financial Overview
Year 2021 2022 2023
Revenue 691 678 753
(USD Million)
7.8.4 Product Portfolio
System Information
Myriad offers tests to assess an individual's risk for hereditary
cancer syndromes, such as BRCA1 and BRCA2 mutations
Hereditary Cancer Testing
associated with breast and ovarian cancer, as well as mutations
linked to other cancers like colon, prostate, and pancreatic cancer.
Myriad provides genetic screening tests for pregnant women to
Prenatal Screening assess the risk of certain chromosomal abnormalities in the fetus,
such as Down syndrome, trisomy 18, and trisomy 13.
These tests are designed to identify individuals who carry genetic
Carrier Screening
mutations that could be passed on to their children and increase
176 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 177
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
the risk of certain inherited disorders, such as cystic fibrosis,
spinal muscular atrophy, and Fragile X syndrome.
Myriad offers tests to analyze how an individual's genetic makeup
may affect their response to certain medications, helping
Pharmacogenomic Testing
healthcare providers tailor treatment plans for optimal
effectiveness and minimal side effects.
Tests are available to assess the genetic risk factors for inherited
Hereditary Cardiovascular Testing cardiovascular conditions such as hypertrophic cardiomyopathy
and long QT syndrome.
7.8.5 Key Strategic Developments
Date Development
Myriad Genetics, Inc., a leader in genetic testing and precision
medicine, announced it has completed the acquisition from
February 2024
Intermountain Health of select assets from its Intermountain
Precision Genomics (IPG) laboratory business, including the
177 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 178
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-
certified laboratory in St. George, Utah.
Myriad Genetics, Inc., a leader in genetic testing and precision
medicine, announced it has entered into a definitive agreement to
acquire select assets from Intermountain Precision Genomics’
January 2024 (IPG) laboratory business, including the Precise™ Tumor Test, the
Precise Liquid Test, and IPG’s CLIA-certified laboratory in St.
George, Utah where the Precise Tumor Test is currently
performed.
178 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Page 179
2 2
0 0
2
2 APAC Genetic Testing Market Study, Opportunities & Forecast 2020-2032
3
3
Disclaimer
The information and opinions in this report were prepared by the Straits Research team. The information herein is believed to be reliable and has been obtained
from authentic public sources, and as per the analyst’s perspective and understanding of the market. Our customers acknowledge, when ordering, that research
and analysis are for our customers ‘internal use and not for general publication or disclosure to third parties’, unless consent provided explicitly on email by Straits
Research team. This document contains confidential information and is the exclusive property of Straits Research. Any reproduction, distribution, or quotation of
its contents, in whole or in part, is strictly prohibited without prior written consent from Straits Research. This document is intended solely for the use of the
purchasing client and may not be shared with any third party without explicit authorization. For further details on usage terms, please refer to the accompanying
disclaimer.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Straits Research does not endorse any vendors,
Technology or Duration depicted in their research publications. Straits Research and analysis publications consist of the opinions of research and should not be
construed as statements of fact. Straits Research disclaims all warranties, expressed or implied, with respect to this research, including any warranties of
merchantability or fitness for a particular purpose.
Straits Research takes no responsibility for any incorrect information supplied to us by manufacturers or users or by external databases. All trademarks, copyrights
and other of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced
in any Technology without the prior written agreement of their owner. No part of this strategic analysis may be given, lent, resold or disclosed to noncustomers
without the written permission of Straits Research. Any concerns with the scope and definition of the market needs to be understood and cleared from the Straits
Research team by the customer before purchasing. Furthermore, please note that any issues arising from the use of the data provided in this report shall not be
the responsibility of Straits Research. Straits Research, its parent/subsidiary companies, analysts, or management shall not be held liable or accountable to any
party for questions or issues arising from the data or analysis provided herein. The information presented in this report represents the perspective of our analysts
and should be utilized for business decisions at your own risk. It is important to acknowledge that the content or data included in this document, whether in sample
form or in the final deliverables, does not constitute financial, legal, investment, strategic, or marketing advice. The data should be regarded as a reference point
for your own market study and understanding. Any losses, legal issues, or problems incurred as a result of using the information in the sample or final report shall
not be attributed to Straits Research, its parent/subsidiary companies, analysts, or management.
179 Copyright @ Straits Research | sales@straitsresearch.com | www.straitsresearch.com
Names mentioned 67 people and organisations named in the text · linked when the evidence is strong
unresolved
org
F. Hoffmann-La Roche Ltd
p.9 ×3
unresolved
org
Agilent Technologies Inc
p.10 ×3
unresolved
org
Illumina Inc
p.10 ×3
unresolved
org
Thermos Fisher Scientific Inc
p.11
unresolved
org
CSL Ltd
p.11 ×3
unresolved
org
Bio-Rad Laboratories Inc
p.11 ×3
unresolved
org
Myriad Genetics Inc
p.11 ×2
unresolved
—
Severin Schwan
p.118
unresolved
—
Matt Sause
p.118
unresolved
—
Thomas Schinecker
p.118
unresolved
—
Cristina A. Wilbur
p.118
unresolved
—
Levi Garraway
p.118
unresolved
—
Jürgen Steinemann
p.118
unresolved
—
Olivier Verscheure
p.118
unresolved
—
Mike McMullen
p.124
unresolved
—
Henrik Ancher-Jensen
p.124
unresolved
—
Allison Ballmer
p.124
unresolved
—
Philip Binns
p.124
unresolved
—
Mala Anand
p.124
unresolved
—
ROBERT B. FORD
p.130
unresolved
—
HUBERT L. ALLEN
p.130
unresolved
—
LISA D. EARNHARDT
p.130
unresolved
—
ROBERT E. FUNCK, JR.
p.130
unresolved
—
JOSEPH MANNING
p.130
unresolved
—
MARY K. MORELAND
p.130
unresolved
—
LOUIS H. MORRONE
p.130
unresolved
person
H. MORRONE
p.130
unresolved
org
Illumina Inc Illumina Inc.
p.136
unresolved
—
Stephen P. MacMillan
p.139
unresolved
—
Jacob Thaysen
p.139
unresolved
—
Charles Dadswell
p.139
unresolved
—
Steve Barnard
p.139
unresolved
—
Nicole Berry
p.139
unresolved
—
Ankur Dhingra
p.139
unresolved
—
Pat Leckman
p.139
unresolved
—
Kevin Pegels
p.139
unresolved
—
Carissa Rollins
p.139
unresolved
—
Salli Schwartz
p.139
unresolved
—
Bas Verhoef
p.139
unresolved
org
Development Illumina Inc.
p.143
unresolved
org
Thermos Fisher Scientific Inc Thermo Fisher Scientific Inc.
p.145
unresolved
org
Thermo Fisher Scientific Inc
p.146 ×3
unresolved
—
Marc N. Casper
p.148
unresolved
—
Stephen Williamson
p.148
unresolved
—
Michel Lagarde
p.148
unresolved
—
Lisa P. Britt
p.148
unresolved
—
Sandy Pound
p.148
unresolved
—
Aditya Joshi
p.148
unresolved
—
Ryan Snyder
p.148
unresolved
—
Karen E. Nelson
p.148
unresolved
org
Development Thermo Fisher Scientific Inc.
p.153
unresolved
org
CSL Ltd CSL Ltd
p.155
unresolved
—
Paul McKenzie
p.158
unresolved
—
Greg Boss
p.158
unresolved
—
Hervé Gisserot
p.158
unresolved
org
Bio-Rad Laboratories Inc Bio-Rad Laboratories Inc
p.163
unresolved
org
US. Bio-Rad Laboratories Inc
p.163
unresolved
org
QIAGEN N.V.
p.169
unresolved
org
U.S. District Court
p.169
unresolved
org
Myriad Genetics Inc Myriad Genetics Inc
p.171
unresolved
org
US. Myriad Genetics Inc
p.171
unresolved
person
Dr. Kevin R. Haas
p.175
unresolved
—
Scott Leffler
p.175
unresolved
person
Dr. Dale Muzzey
p.175
unresolved
—
Sam Raha
p.175
unresolved
—
Shereen Solaiman
p.175
unresolved
—
Mark S. Verratti
p.175
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
Rule parser
Needs review
confidence 0.091
16300 ms
12 Sep 2026 23:04
Raw output
{'appraiser_exempt': None,
'appraiser_name': '',
'assets': [],
'currency': None,
'fact_type': '',
'issuer_name': '',
'kind': 'MATERIAL_FACT',
'kjpp_name': '',
'letter_number': '',
'object_text': '',
'object_truncated': False,
'parties': [],
'pct_of_equity': None,
'reference_period': '',
'requires_rups': None,
'rups_date': None,
'ticker': '',
'transaction_date': None,
'valuation_date': None,
'value': None}